CECO Environmental Reports First Quarter 2026 Results

Strong First Quarter Results Highlighted by Orders up 97 Percent and Backlog Eclipsing $1B

Largest Natural Gas Power Order in Company History Booked in April 2026

Company Raises Full Year 2026 Guidance

ADDISON, Texas, April 28, 2026 (GLOBE NEWSWIRE) — CECO Environmental Corp. (Nasdaq: CECO) (“CECO”), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment, and industrial equipment, today reported its financial results for the first quarter of 2026 as well as an update for the proposed merger transaction with Thermon Group Holdings, Inc. (“Thermon”).


Highlights for the Quarter


(1)

  • Orders of $449.5 million, up 97 percent
  • Backlog of $1,035.1 million, up 72 percent
  • Revenue of $205.9 million, up 17 percent
  • Gross profit of $63.9 million, up 3 percent; Gross margin of 31.0 percent
  • Net loss of $(0.4) million, down 101 percent; non-GAAP net income of $13.9 million, up 297 percent
  • GAAP EPS (diluted) of $(0.01); non-GAAP EPS (diluted) of $0.36
  • Adjusted EBITDA of $20.4 million, up 46 percent
  • Free cash flow of $(15.7) million, down 4 percent

(1) All comparisons are versus the comparable prior year period, unless otherwise stated.
Reconciliations of GAAP (reported) to non-GAAP measures are in the attached financial tables.

Todd Gleason, CECO’s Chief Executive Officer commented, “I am pleased to highlight the tremendous topline growth and steady EBITDA margin expansion we continue to deliver at CECO. This is the first time our quarter-end backlog has eclipsed $1 billion, which reflects our incredible 2.2 book-to-bill ratio during the first quarter. We continue to secure strategic, large-scale projects to enable natural gas power generation expansion in support of a tremendous global investment in electrical power demand for data centers, artificial intelligence computing, industrial reshoring and electrification. This strong momentum continued into April 2026 as we have already booked approximately over $450 million in new orders including the largest ever order in the Natural Gas Power market, setting our second quarter bookings on a course to materially exceed the record we just set in the first quarter.”

First quarter operating income was $1.9 million, down $60.0 million or 97 percent when compared to $61.9 million in the first quarter 2025. On an adjusted basis, non-GAAP operating income was $17.9 million, up $9.3 million or 108 percent when compared to $8.6 million in the first quarter of 2025. Net loss was $(0.4) million in the quarter, down $36.4 million or 101 percent when compared to net income of $36.0 million in the first quarter of 2025. Non-GAAP net income was $13.9 million, up $10.4 million or 297 percent when compared to $3.5 million in the first quarter of 2025. Adjusted EBITDA of $20.4 million, reflecting a margin of 9.9 percent, was up $6.4 million or 46 percent compared to $14.0 million in the first quarter of 2025. Free cash flow in the quarter was $(15.7) million, down $0.6 million or 4 percent compared to $(15.1) million in the first quarter of 2025.

“Our adjusted EBITDA margin expansion of almost 200 basis points reflects our improving volume conversion and the early, positive results of early implementation of our 80/20 programs – which are designed to improve efficiencies and provide operating benefits from commercial and operational simplification. While gross margins did experience contraction in Q1, this was anticipated given last year’s sale of the higher margin but non-strategic global pump business combined with the timing of lower margin jobs booked in early 2025. As we progress throughout 2026 our backlog profile reflects higher margin projects, thus we expect higher gross margins in Q2 and throughout the remainder of the year. Currently, we see no material impact from the Iran War or higher inflation, but we are monitoring the situation and are strategically prepared with additional price and cost actions, if appropriate,” added Gleason.



2026 Full Year Guidance Update

The Company raises its full year outlook for 2026 to reflect revenue between $940 million and $1 billion, up approximately 25 percent at the midpoint of the range when compared to 2025 and increases full year Adjusted EBITDA between $120 and $140 million, up approximately 45 percent at the midpoint of the range. This compares to the previous guidance range of revenue between $925 and $975 million, and adjusted EBITDA between $115 and $135 million. The Company reiterates its full year free cash flow of at least 50% of Adjusted EBITDA.  The Company’s full year outlook excludes the impact of the transaction with Thermon.   

“Given another strong start to the year with our record backlog and accelerating orders pace, we are raising our full year 2026 outlook. We now expect organic revenues to grow 25 percent, and adjusted EBITDA to grow almost 45 percent. Separately, the acquisition of Thermon remains very much on track for a second quarter close. Just a few weeks ago, Thermon issued a press release highlighting exciting orders with their liquid load bank solution, which is a new product for data center markets. The combination of CECO and Thermon will yield a double-digit growth company with attractive margins and operating cash flows. We remain confident the combination will also unlock at least $40 million in cost synergies and meaningful commercial opportunities. I look forward to sharing more updates and a combined company financial outlook soon,” concluded Gleason.


Thermon Transaction Update

CECO and Thermon continue to progress toward completion of the previously announced merger. The registration statement on Form S-4 has been declared effective by the SEC, and CECO and Thermon have mailed the definitive joint proxy statement/prospectus to their respective stockholders. Stockholder votes are expected to take place on May 27, 2026, as described in the joint proxy statement/prospectus. The transaction is expected to close in June.

EARNINGS CONFERENCE CALL


A conference call is scheduled for today at 8:30 a.m. ET to discuss the first quarter 2026 financial results. Please visit the Investor Relations portion of the website (https://investors.cecoenviro.com) to listen to the call via webcast. The conference call may also be accessed by visiting https://edge.media-server.com/mmc/p/o4vmw7mt.

A replay of the conference call will be available on the Company’s website for a period of one year. The replay may also be accessed by visiting https://edge.media-server.com/mmc/p/o4vmw7mt.


ABOUT CECO ENVIRONMENTAL

CECO Environmental is a leading environmentally focused, diversified industrial company, serving the broad landscape of industrial air, industrial water and energy transition markets globally providing innovative solutions and application expertise. CECO helps companies grow their business with safe, clean, and more efficient solutions that help protect people, the environment and industrial equipment.  CECO solutions improve air and water quality, optimize emissions management, and increase energy efficiency for highly-engineered applications in power generation, midstream and downstream hydrocarbon processing and transport, electric vehicle production, polysilicon fabrication, semiconductor and electronics, battery production and recycling, specialty metals and steel production, beverage can, and water/wastewater treatment and a wide range of other industrial end markets. CECO is listed on Nasdaq under the ticker symbol “CECO.” Incorporated in 1966, CECO’s global headquarters is in Addison, Texas. For more information, please visit www.cecoenviro.com.

Company Contact:
Marcio Pinto
Vice President – Corporate Integration and Investor Relations
888-990-6670
[email protected]

Investor Relations Contact:

Steven Hooser and Jean Marie Young
Three Part Advisors, LLC
214-872-2710
[email protected]

No Offer or Solicitation

This communication is for informational purposes only and is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Additional Information and Where to Find It

This communication relates to the proposed merger transaction (the “Proposed Transaction”) involving Thermon and CECO, among other things. The issuance of shares of CECO common stock in connection with the Proposed Transaction is being submitted to the stockholders of CECO for their consideration, and the Proposed Transaction is being submitted to the stockholders of Thermon for their consideration. In connection therewith, CECO filed with the SEC a registration statement on Form S-4 (the “Registration Statement”) that included a joint proxy statement/prospectus (the “Joint Proxy Statement/Prospectus”), and the Registration Statement has been declared effective by the SEC. CECO and Thermon have mailed the definitive Joint Proxy Statement/Prospectus to their respective stockholders. Each of CECO and Thermon may also file other relevant documents with the SEC regarding the Proposed Transaction. This communication is not a substitute for the Joint Proxy Statement/Prospectus or any other document that CECO or Thermon, as applicable, has filed or may file with the SEC in connection with the Proposed Transaction. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND SECURITY HOLDERS OF CECO AND THERMON ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT HAVE BEEN OR MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT CECO, THERMON, THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and security holders may obtain free copies of the definitive Joint Proxy Statement/Prospectus, as well as other filings containing important information about CECO, Thermon and the Proposed Transaction, through the website maintained by the SEC at https://www.sec.gov. Copies of the documents filed with the SEC by CECO are available free of charge on CECO’s website at https://investors.cecoenviro.com. Copies of the documents filed with the SEC by Thermon are available free of charge on Thermon’s website at https://ir.thermon.com. The information included on, or accessible through, CECO’s or Thermon’s website is not incorporated by reference into this communication.

Participants in the Solicitation

CECO, Thermon and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the Proposed Transaction.

Information about the directors and executive officers of CECO, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in (i) the definitive Joint Proxy Statement/Prospectus filed by CECO (and which is available at https://www.sec.gov/Archives/edgar/data/3197/000110465926047714/tm2611145-7_424b3.htm) and (ii) to the extent holdings of CECO’s securities by the directors or executive officers of CECO have changed since the amounts set forth in the definitive Joint Proxy Statement/Prospectus, such changes have been or will be reflected on Initial Statement of Beneficial Ownership of Securities on Form 3, Statement of Changes in Beneficial Ownership on Form 4, or Annual Statement of Changes in Beneficial Ownership on Form 5 filed with the SEC, which are available at https://www.sec.gov/cgi-bin/own-disp?action=getissuer&CIK=0000003197.

Information about the directors and executive officers of Thermon, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in (i) Thermon’s proxy statement for its 2025 Annual Meeting of Stockholders, which was filed with the SEC on June 18, 2025 (and which is available at https://www.sec.gov/Archives/edgar/data/1489096/000148909625000097/thr-20250618.htm), (ii) the definitive Joint Proxy Statement/Prospectus filed by Thermon (and which is available at https://www.sec.gov/Archives/edgar/data/1489096/000110465926047723/tm2612301-1_defm14a.htm) and (iii) to the extent holdings of Thermon’s securities by the directors or executive officers of Thermon have changed since the amounts set forth in the definitive Joint Proxy Statement/Prospectus, such changes have been or will be reflected on Initial Statement of Beneficial Ownership of Securities on Form 3, Statement of Changes in Beneficial Ownership on Form 4, or Annual Statement of Changes in Beneficial Ownership on Form 5 filed with the SEC, which are available at https://www.sec.gov/cgi-bin/own-disp?action=getissuer&CIK=0001489096.

Investors should read the Joint Proxy Statement/Prospectus carefully before making any voting or investment decisions. You may obtain free copies of these documents from CECO and Thermon using the sources indicated above.

Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements, other than statements of historical fact, included in this Form 8-K that address events, or developments that CECO and Thermon expect, believe, or anticipate will or may occur in the future are forward-looking statements. The words “intend,” “expect,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this communication, but are not limited to, statements regarding the Proposed Transaction, pro forma descriptions of the combined company and its operations, integration and transition plans, synergies, opportunities and anticipated future performance. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking.

There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements included in this communication. These include the expected timing and likelihood of completion of the Proposed Transaction, including the timing, receipt and terms and conditions of any required governmental and regulatory approvals of the Proposed Transaction that could reduce anticipated benefits or cause the parties to abandon the Proposed Transaction, the ability to successfully integrate the businesses, the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement, the possibility that stockholders of CECO or Thermon may not approve the Proposed Transaction, the risk that the parties may not be able to satisfy the conditions to the Proposed Transaction in a timely manner or at all, risks related to disruption of management time from ongoing business operations due to the Proposed Transaction, the risk that any announcements relating to the Proposed Transaction could have adverse effects on the market price of CECO’s common stock or Thermon’s common stock, the risk that the Proposed Transaction and its announcement could have an adverse effect on the ability of CECO and Thermon to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on their operating results and businesses generally, the risk the pending Proposed Transaction could distract management of both entities and they will incur substantial costs, the risk that problems may arise in successfully integrating the businesses of the companies, which may result in the combined company not operating as effectively and efficiently as expected, the risk that the combined company may be unable to achieve synergies or it may take longer than expected to achieve those synergies and other important factors that could cause actual results to differ materially from those projected. All such factors are difficult to predict and are beyond CECO’s or Thermon’s control, including those detailed in CECO’s annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K that are available on its website at https://investors.cecoenviro.com and on the SEC’s website at https://www.sec.gov, and those detailed in Thermon’s annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K that are available on Thermon’s website at https://ir.thermon.com and on the SEC’s website at https://www.sec.gov.

All forward-looking statements are based on assumptions that CECO or Thermon believe to be reasonable but that may not prove to be accurate. Such forward-looking statements are based on assumptions and analyses made by CECO and Thermon in light of their perceptions of current conditions, expected future developments, and other factors that CECO and Thermon believe are appropriate under the circumstances. These statements are subject to a number of known and unknown risks and uncertainties. Forward-looking statements are not guarantees of future performance and actual events may be materially different from those expressed or implied in the forward-looking statements. The forward-looking statements in this communication speak as of the date of this communication.

Neither CECO nor Thermon undertakes, and each of them expressly disclaims, any duty to update any forward-looking statement whether as a result of new information, future events or otherwise, except as required by law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as the date hereof.

CECO ENVIRONMENTAL CORP.
CONSOLIDATED BALANCE SHEETS






(in thousands, except per share data)   March 31, 2026     December 31, 2025  
ASSETS            
Current assets:            
Cash and cash equivalents   $ 45,411     $ 33,144  
Restricted cash     96       83  
Accounts receivable, net of allowances of $5,306 and $9,866     278,528       172,909  
Costs and estimated earnings in excess of billings on uncompleted contracts     103,720       115,614  
Inventories     60,175       53,996  
Prepaid expenses and other current assets     40,739       29,450  
Prepaid income taxes     10,564       4,986  
Total current assets     539,233       410,182  
Property, plant and equipment, net     48,092       47,808  
Right-of-use assets from operating leases     29,181       28,251  
Goodwill     291,128       288,163  
Intangible assets – finite life, net     99,167       96,966  
Intangible assets – indefinite life     9,678       9,705  
Deferred income taxes           449  
Deferred charges and other assets     10,896       12,245  
Total assets   $ 1,027,375     $ 893,769  
LIABILITIES AND SHAREHOLDERS’ EQUITY            
Current liabilities:            
Current portion of debt   $ 5,340     $ 1,879  
Accounts payable     137,594       117,848  
Accrued expenses     71,212       57,639  
Billings in excess of costs and estimated earnings on uncompleted contracts     184,223       123,726  
Income taxes payable     7,424       4,738  
Total current liabilities     405,793       305,830  
Other liabilities     7,033       3,317  
Debt, less current portion     247,907       210,559  
Deferred income tax liability, net     26,336       27,920  
Operating lease liabilities     23,106       22,961  
Total liabilities     710,175       570,587  
Commitments and contingencies (See Note 14)            
Shareholders’ equity:            
Preferred stock, $0.01 par value; 10,000 shares authorized, none issued            
Common stock, $0.01 par value; 100,000,000 shares authorized, 35,840,781 and
35,644,537 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively
    357       355  
Capital in excess of par value     264,595       269,453  
Retained earnings     56,223       56,621  
Accumulated other comprehensive loss     (8,976 )     (8,901 )
Total CECO shareholders’ equity     312,199       317,528  
Noncontrolling interest     5,001       5,654  
Total shareholders’ equity     317,200       323,182  
Total liabilities and shareholders’ equity   $ 1,027,375     $ 893,769  

CECO ENVIRONMENTAL CORP.
CONSOLIDATED STATEMENTS OF INCOME
(unaudited)

    Three months ended March 31,  
(in thousands, except share and per share data)   2026     2025  
Net sales   $ 205,919     $ 176,697  
Cost of sales     142,000       114,535  
Gross profit     63,919       62,162  
Selling and administrative expense     46,091       53,542  
Amortization expense     4,003       3,096  
Acquisition and integration expense     10,280       8,143  
Gain on sale of Global Pump Solutions business           (64,502 )
Other operating expense     1,670       13  
Income from operations     1,875       61,870  
Other expense     1,392       594  
Interest expense     4,230       6,217  
(Loss) income before income taxes     (3,747 )     55,059  
Income tax (benefit) expense     (3,499 )     18,617  
Net (loss) income     (248 )     36,442  
Noncontrolling interest     150       458  
Net (loss) income attributable to CECO Environmental Corp.   $ (398 )   $ 35,984  
Loss (earnings) per share:            
Basic   $ (0.01 )   $ 1.03  
Diluted   $ (0.01 )   $ 0.98  
Weighted average number of common shares outstanding:            
Basic     35,690,813       35,028,301  
Diluted     35,690,813       36,689,320  

CECO ENVIRONMENTAL CORP.
CONSOLIDATED STATEMENTS OF CASH FLOWS

    Three months ended March 31,  
(in thousands)   2026     2025  
Cash flows from operating activities:            
Net (loss) income   $ (248 )   $ 36,442  
Adjustments to reconcile net (loss) income to net cash used in operating activities:            
Depreciation and amortization     6,104       5,115  
Unrealized foreign currency loss (gain)     624       (1,142 )
Gain on sale of Global Pump Solutions business           (64,502 )
Loss on sale of property and equipment     (219 )     (15 )
Debt discount amortization     199       206  
Share-based compensation expense     440       3,356  
(Recovery) allowance for credit loss     (1,517 )     819  
Inventory obsolescence expense     1,082       92  
Deferred income tax (benefit) expense     (1,152 )     166  
Changes in operating assets and liabilities, net of acquisitions and divestiture:            
Accounts receivable     (103,137 )     16,215  
Costs and estimated earnings in excess of billings on uncompleted contracts     11,612       (12,270 )
Inventories     (6,851 )     (2,416 )
Prepaid expense and other current assets     (17,016 )     (17,652 )
Deferred charges and other assets     1,534       (971 )
Accounts payable     19,649       (3,633 )
Accrued expenses     12,681       8,865  
Billings in excess of costs and estimated earnings on uncompleted contracts     60,667       5,933  
Income taxes payable     2,700       17,220  
Other liabilities     (252 )     (3,524 )
Net cash used in operating activities     (13,100 )     (11,696 )
Cash flows from investing activities:            
Acquisitions of property and equipment     (2,589 )     (3,385 )
Net cash proceeds for sale of Global Pump Solutions business           105,860  
Cash paid for acquisitions, net of cash acquired     (6,616 )     (97,646 )
Net cash (used in) provided by investing activities     (9,205 )     4,829  
Cash flows from financing activities:            
Borrowings on revolving credit lines     57,700       148,100  
Repayments on revolving credit lines     (14,500 )     (27,600 )
Repayments of long-term debt     (435 )     (420 )
Payments on finance leases and financing liability           (234 )
Deferred financing fees paid     (2,156 )      
Deferred consideration paid for acquisitions           (1,000 )
Equity awards surrendered by employees for tax liability, net of proceeds from employee stock purchase plan and exercise of stock options     (5,166 )     (2,688 )
Noncontrolling interest distributions     (803 )     (402 )
Net cash provided by financing activities     34,640       115,756  
Effect of exchange rate changes on cash, cash equivalents and restricted cash     (56 )     (414 )
Net increase in cash, cash equivalents and restricted cash     12,280       108,475  
Cash, cash equivalents and restricted cash at beginning of period     33,227       38,201  
Cash, cash equivalents and restricted cash at end of period   $ 45,507     $ 146,676  
Cash paid during the period for:            
Interest   $ 4,037     $ 3,987  
Income taxes   $ 486     $ 2,405  

CECO ENVIRONMENTAL CORP.
RECONCILIATION OF GAAP TO NON-GAAP MEASURES

    Three months ended March 31,  
(in millions, except share data)   2026     2025  
Net (loss) income as reported in accordance with GAAP   $ (0.4 )   $ 36.0  
Amortization expenses     4.0       3.1  
Acquisition and integration expenses     10.3       8.1  
Gain on sale of Global Pump Solutions business           (64.5 )
Other operating expense     1.7        
Foreign currency remeasurement     1.6       0.6  
Tax (benefit) expense of adjustments     (3.3 )     20.2  
Non-GAAP net income   $ 13.9     $ 3.5  
Depreciation     2.2       2.0  
Non-cash stock compensation     0.4       3.4  
Other income     (0.3 )      
Interest expense     4.2       6.2  
Income tax benefit     (0.2 )     (1.6 )
Noncontrolling interest     0.2       0.5  
Adjusted EBITDA   $ 20.4     $ 14.0  
             
Earnings per share:            
Basic   $ (0.01 )   $ 1.03  
Diluted   $ (0.01 )   $ 0.98  
             
Non-GAAP net income per share:            
Basic   $ 0.39     $ 0.10  
Diluted   $ 0.36     $ 0.10  

  Three months ended March 31,  
(in millions) 2026     2025  
Net cash used in operating activities $ (13.1 )   $ (11.7 )
Acquisitions of property and equipment   (2.6 )     (3.4 )
Free cash flow $ (15.7 )   $ (15.1 )

NOTE REGARDING NON-GAAP FINANCIAL MEASURES

CECO is providing certain non-GAAP historical financial measures as presented above as we believe that these figures are useful to investors and management in evaluating the Company’s ongoing financial performance, and we believe that they provide greater transparency to investors as supplemental information to its GAAP results. A “non-GAAP financial measure” is a numerical measure of a company’s historical financial performance that excludes amounts that are included in the most directly comparable measure calculated and presented in accordance with GAAP.

Non-GAAP operating income, non-GAAP net income, non-GAAP operating margin, non-GAAP earnings per basic and diluted share, adjusted EBITDA, and free cash flow, as presented in the financial data included in this press release, have been adjusted to exclude the effects of acquisition and integration expenses; divestiture gains and expenses; amortization expenses for acquisition-related intangible assets; earn-out expenses (income); restructuring expenses; executive transition expenses; asbestos and other legal matter expenses; foreign currency remeasurement; and the associated tax benefit or cost of these items. Management believes that these items are not necessarily indicative of the Company’s ongoing operations and their exclusion provides individuals with additional information to better compare the Company’s results over multiple periods. Management utilizes this information to evaluate its ongoing financial performance. Our financial statements may continue to be affected by items similar to those excluded in the non-GAAP adjustments described above, and exclusion of these items from our non-GAAP financial measures should not be construed as an inference that all such costs are unusual or infrequent.

Non-GAAP operating income, non-GAAP net income, non-GAAP operating margin, Adjusted EBITDA and free cash flow are not calculated in accordance with GAAP, and should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Non-GAAP financial measures have limitations in that they do not reflect all of the costs associated with the operations of our business as determined in accordance with GAAP. As a result, you should not consider these measures in isolation or as a substitute for analysis of CECO’s results as reported under GAAP. Additionally, CECO cautions investors that non-GAAP financial measures used by the Company may not be comparable to similarly titled measures of other companies.

In accordance with the requirements of Regulation G issued by the Securities and Exchange Commission, non-GAAP operating income, non-GAAP net income, non-GAAP operating margin, non-GAAP earnings per basic and diluted share, adjusted EBITDA and free cash flow stated in the tables above are reconciled to the most directly comparable GAAP financial measures.

Non-GAAP measures presented on a forward-looking basis were not reconciled to the comparable GAAP financial measures because the reconciliation could not be performed without unreasonable efforts. The GAAP measures are not accessible on a forward-looking basis because we are currently unable to predict with a reasonable degree of certainty the type and extent of certain items that would be expected to impact GAAP measures for these periods but would not impact the non-GAAP measures. Such items may include acquisition and integration expenses; divestiture gains and expenses; amortization expenses for acquisition-related intangible assets; earn-out expenses (income); restructuring expenses; executive transition expenses; asbestos and other legal matter expenses; foreign currency remeasurement; and the associated tax benefit or cost of these items.

SAFE HARBOR

Any statements contained in this Press Release, other than statements of historical fact, including statements about management’s beliefs and expectations, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, both as amended, and should be evaluated as such. These statements are made on the basis of management’s views and assumptions regarding future events and business performance. We use words such as “believe,” “expect,” “anticipate,” “intends,” “estimate,” “forecast,” “project,” “will,” “plan,” “should” and similar expressions to identify forward-looking statements. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Potential risks and uncertainties, among others, that could cause actual results to differ materially are discussed under “Part I – Item 1A. Risk Factors” of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and may be included in subsequently filed Quarterly Reports on Form 10-Q, and include, but are not limited to: risks related to the Proposed Transaction with Thermon described herein above; dependence on fixed price contracts and the risks associated therewith, including actual costs exceeding estimates and method of accounting for revenue; the effect of growth on our infrastructure, resources and existing sales; the ability to expand operations in both new and existing markets; the potential for contract delay or cancellation as a result of on-going or worsening supply chain challenges, or other customer-driven project delays relating to supply chain challenges or other customer considerations, including those related to the conflict in the Middle East; liabilities arising from faulty services or products that could result in significant professional or product liability, warranty or other claims; changes in or developments with respect to any litigation or investigation; failure to meet timely completion or performance standards that could result in higher cost and reduced profits or, in some cases, losses on projects; the potential for fluctuations in prices for manufactured components and raw materials, including as a result of tariffs and surcharges, and rising energy costs; inflationary pressures relating to rising raw material costs and the cost of labor; the substantial amount of debt incurred in connection with our strategic transactions and our ability to repay or refinance it or incur additional debt in the future; the impact of federal, state or local government regulations, including with respect to tax policy; our ability to repurchase shares of our common stock and the amounts and timing of repurchases, if any; our ability to successfully realize the expected benefits of our restructuring program; economic and political conditions generally; our ability to optimize our business portfolio by identifying acquisition targets, executing upon any strategic acquisitions or divestitures, integrating acquired businesses and realizing the synergies from strategic transactions; unpredictability and severity of catastrophic events, including cybersecurity threats, acts of terrorism or outbreak of war or hostilities or public health crises, as well as management’s response to any of the aforementioned factors; and our ability to remediate our material weaknesses, or any other material weakness that we may identify in the future, that could result in material misstatements in our financial statements. Many of these risks are beyond management’s ability to control or predict. Should one or more of these risks or uncertainties materialize, or should any related assumptions prove incorrect, actual results may vary in material aspects from those currently anticipated. Investors are cautioned not to place undue reliance on such forward-looking statements as they speak only to our views as of the date the statement is made. Except as required under the federal securities laws or the rules and regulations of the Securities and Exchange Commission, we undertake no obligation to update or review any forward-looking statements, whether as a result of new information, future events or otherwise.



Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026

BEDFORD, Mass., April 28, 2026 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, May 5, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the first quarter ended March 31, 2026.

Conference Call and Webcast Information
:

Date: Tuesday, May 5, 2026 at 8:00 AM ET
Participant Dial-In (U.S.): 1-800-343-4136
Participant Dial-In (International): 1-203-518-9843
Conference ID: OCULAR (required for entry)
Webcast Access: Please click here

The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcasts will be archived for at least 30 days following the presentation.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.

Follow the Company on its website, LinkedIn, or X.

DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media

Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
[email protected]



LGI Homes, Inc. Reports First Quarter 2026 Results and Raises Full Year Margin Guidance

THE WOODLANDS, Texas, April 28, 2026 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) today announced financial results for the three months ended March 31, 2026.

“We are pleased with our first quarter results, which met or exceeded our expectations across nearly every metric,” said Eric Lipar, Chairman and Chief Executive Officer of LGI Homes. “Our teams executed well throughout the quarter and the early weeks of the spring selling season have reinforced our confidence in the year ahead.

“In the first quarter, we delivered a total of 916 homes. 881 home closings contributed to revenue of $319.7 million and the profits from the sale of 35 currently or previously leased homes were recognized in other income. Notably, our average sales price per home closed increased 2.9% to $362,924, demonstrating our ability to preserve pricing while continuing to support affordability through targeted price discounts and financing strategies. We are pleased with our margin performance, including delivering an adjusted gross margin of 23.4%, exceeding our previous guidance range and further demonstrating our continued focus on cost discipline.

“Our teams remained focused on driving leads, managing inventory, and executing on sales initiatives that directly contributed to ending the quarter with 1,699 homes in backlog, up 63.4% compared to the same period last year and 21.9% sequentially.

“The performance to date in 2026 reinforces our confidence in the full‑year guidance we shared on our last call. Additionally, based on first quarter margins exceeding our previous guidance range, we are raising full year gross margin guidance to between 18.5% and 20.5% and adjusted gross margin between 22.0% and 24.0%.”

Mr. Lipar concluded, “Our first quarter results reflect the strength of our operating model and the dedication of our teams across the country. The structural advantages of our self-developed land pipeline, combined with our disciplined approach to pricing and inventory management, continue to support our margins and position us to perform through varying market conditions.”


First


Quarter


2026


Highlights

  • Home sales revenues of $319.7 million
  • Home closings of 881
  • Total home closings of 916, including 35 currently and previously leased homes
  • Average sales price per home closed of $362,924
  • Gross margin as a percentage of home sales revenues of 18.7%
  • Gross margin excluding inventory impairment* as a percentage of home sales revenues of 20.2%
  • Adjusted gross margin* as a percentage of home sales revenues of 23.4%
  • Net income before income taxes of $4.3 million
  • Net income of $2.2 million or $0.09 basic EPS and $0.09 diluted EPS
  • Adjusted net income* of $5.6 million, or $0.24 adjusted basic EPS* and $0.24 adjusted diluted EPS*

*Please see “

Non-GAAP Measures

” for a reconciliation of Gross Margin Excluding Inventory Impairment (a non-GAAP measure) and Adjusted Gross Margin (a non-GAAP measure) to Gross Margin, and Adjusted Net Income (a non-GAAP measure) to Net Income, the most directly comparable GAAP measures and for calculations of adjusted basic EPS and adjusted diluted EPS.


Balance Sheet Highlights

  • Total liquidity of $355.0 million at March 31, 2026, including cash and cash equivalents of $60.9 million and $294.2 million of availability under the Company’s revolving credit facility
  • Net debt to capital ratio* of 44.0% at March 31, 2026

*Please see “

Non-GAAP Measures

” for a reconciliation of net debt to capital ratio (a non-GAAP measure) to debt to capital ratio, the most directly comparable GAAP measure.

Full Year
2026
Outlook

Subject to the caveats in the Forward-Looking Statements section of this press release and the assumptions noted below, the Company is updating its gross margin and adjusted gross margin as a percentage of home sales revenues outlook for the full year 2026 and reiterating its other outlook items for the full year 2026. Currently, the Company expects for full year 2026:

  • Home closings between 4,600 and 5,400
  • Active selling communities at the end of 2026 between 150 and 160
  • Average sales price per home closed between $355,000 and $365,000
  • Gross margin as a percentage of home sales revenues between 18.5% and 20.5%, adjusted for estimated capitalized interest and estimated purchase accounting of approximately 3.5%, which results in Adjusted gross margin (non-GAAP) as a percentage of home sales revenues between 22.0% and 24.0%
  • SG&A as a percentage of home sales revenues between 15.0% and 16.0%
  • Effective tax rate of approximately 26.5%

This outlook assumes that general economic conditions, including input costs, materials, product and labor availability, interest rates and mortgage availability, in the remainder of 2026 are similar to those experienced to date in 2026 and that the average sales price per home closed, construction costs, availability of land and land development costs for the remainder of 2026 are consistent with the Company’s recent experience. In addition, this outlook assumes that governmental regulations relating to land development and home construction are similar to those currently in place and does not take into account any additional changes to U.S. trade policies, including the imposition of tariffs and duties on homebuilding products.

Earnings Conference Call

The Company will host a conference call via live webcast for investors and other interested parties beginning at 12:30 p.m. Eastern Time on Tuesday, April 28, 2026 (the “Earnings Call”).

Participants may access the live webcast by visiting the Investor Relations section of the Company’s website at https://investor.lgihomes.com.

An archive of the Earnings Call webcast will be available for replay on the Company’s website for one year from the date of the Earnings Call.

About LGI Homes, Inc.

Headquartered in The Woodlands, Texas, LGI Homes, Inc. is a pioneer in the homebuilding industry, successfully applying an innovative and systematic approach to the design, construction and sale of homes across 36 markets in 21 states. LGI Homes has closed over 80,000 homes since its founding in 2003 and has delivered profitable financial results every year. Nationally recognized for its quality construction and exceptional customer service, LGI Homes was named to Newsweek’s list of the World’s Most Trustworthy Companies. LGI Homes’ commitment to excellence extends to its more than 1,000 employees, earning the Company numerous workplace awards at the local, state, and national level, including the Top Workplaces USA 2026 Award. For more information about LGI Homes and its unique operating model focused on making the dream of homeownership a reality for families across the nation, please visit the Company’s website at www.lgihomes.com.

Forward-Looking Statements

Any statements made in this press release or on the Earnings Call that are not statements of historical fact, including statements about the Company’s beliefs, outlook and expectations, are forward-looking statements within the meaning of the federal securities laws, and should be evaluated as such. Forward-looking statements include information concerning expected 2026 home closings, active selling communities, average sales price per home closed, gross margin as a percentage of home sales revenues, adjusted gross margin as a percentage of homes sales revenues, SG&A as a percentage of home sales revenues and effective tax rate, as well as market conditions and possible or assumed future results of operations, including descriptions of the Company’s business plan and strategies. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “objective,” “plan,” “potential,” “predict,” “projection,” “should,” “will” or, in each case, their negative, or other variations or comparable terminology. For more information concerning factors that could cause actual results to differ materially from those contained in the forward-looking statements, please refer to the “Risk Factors” section in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, including the “Cautionary Statement about Forward-Looking Statements” subsection within the “Risk Factors” section, and subsequent filings by the Company with the U.S. Securities and Exchange Commission (the “SEC”), including the “Risk Factors” and “Cautionary Statement about Forward-Looking Statements” sections in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 when it is filed with the SEC. The Company bases these forward-looking statements or outlook on its current expectations, plans and assumptions that it has made in light of its experience in the industry, as well as its perceptions of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances and at such time. As you read and consider this press release or listen to the Earnings Call, you should understand that these statements are not guarantees of future performance or results. The forward-looking statements, including the Company’s 2026 outlook, are subject to and involve risks, uncertainties and assumptions and you should not place undue reliance on these forward-looking statements or outlook. Although the Company believes that these forward-looking statements and outlook are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect the Company’s actual results to differ materially from those expressed in the forward-looking statements and outlook. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. If the Company does update one or more forward-looking statements, there should be no inference that it will make additional updates with respect to those or other forward-looking statements.

LGI HOMES, INC.

CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands, except share data)

    March 31,   December 31,
      2026       2025  
ASSETS        
Cash and cash equivalents   $ 60,860     $ 61,247  
Accounts receivable     45,011       32,467  
Real estate inventory     3,540,731       3,520,563  
Pre-acquisition costs and deposits     24,970       28,950  
Property and equipment, net     124,805       107,145  
Other assets     192,849       154,948  
Deferred tax assets, net     8,921       9,904  
Goodwill     12,018       12,018  
Total assets   $ 4,010,165     $ 3,927,242  
         
LIABILITIES AND EQUITY        
Accounts payable   $ 38,569     $ 16,179  
Accrued expenses and other liabilities     159,725       157,971  
Notes payable     1,709,457       1,656,803  
Total liabilities     1,907,751       1,830,953  
         
COMMITMENTS AND CONTINGENCIES        
EQUITY        
Common stock, par value $0.01, 250,000,000 shares authorized, 27,888,871 shares issued and 23,232,279 shares outstanding as of March 31, 2026 and 27,789,678 shares issued and 23,133,086 shares outstanding as of December 31, 2025     278       277  
Additional paid-in capital     351,272       347,308  
Retained earnings     2,160,499       2,158,339  
Treasury stock, at cost, 4,656,592 shares as of March 31, 2026 and December 31, 2025     (409,635 )     (409,635 )
Total equity     2,102,414       2,096,289  
Total liabilities and equity   $ 4,010,165     $ 3,927,242  

LGI HOMES, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except share and per share data)

    Three Months Ended March 31,
      2026       2025  
Home sales revenues   $ 319,736     $ 351,420  
         
Cost of sales     259,807       277,707  
Selling expenses     32,650       42,342  
General and administrative     27,861       31,202  
Operating income (loss)     (582 )     169  
Other income, net     (4,901 )     (5,555 )
Net income before income taxes     4,319       5,724  
Income tax provision     2,159       1,730  
Net income   $ 2,160     $ 3,994  
Earnings per share:        
Basic   $ 0.09     $ 0.17  
Diluted   $ 0.09     $ 0.17  
         
Weighted average shares outstanding:        
Basic     23,149,912       23,396,470  
Diluted     23,219,224       23,466,746  



Home Sales Revenues, Home Closings, Average Sales Price Per Home Closed (ASP), Average Community Count, Average Monthly Absorption Rate, and Ending Community Count by Reportable Segment



(Revenues in thousands, unaudited)

    Three Months Ended March 31, 2026   As of March 31, 2026
Reportable Segment   Revenues   Home Closings   ASP   Average Community Count   Average Monthly Absorption Rate   Community Count at End of Period
Central   $ 89,160   296   $ 301,216   47.0   2.1   47
Southeast     72,323   219     330,242   29.7   2.5   29
Northwest     37,006   66     560,697   14.3   1.5   15
West     75,850   172     440,988   26.7   2.1   28
Florida     45,397   128     354,664   23.0   1.9   23
Total   $ 319,736   881   $ 362,924   140.7   2.1   142

    Three Months Ended March 31, 2025   As of March 31, 2025
Reportable Segment   Revenues   Home Closings   ASP   Average Community Count   Average Monthly Absorption Rate   Community Count at End of Period
Central   $ 101,146   330   $ 306,503   51.0   2.2   50
Southeast     101,682   312     325,904   29.3   3.5   30
Northwest     34,237   65     526,723   16.7   1.3   16
West     66,956   159     421,107   25.7   2.1   25
Florida     47,399   130     364,608   25.3   1.7   25
Total   $ 351,420   996   $ 352,831   148.0   2.2   146



Owned and Controlled Lots

The table below shows (i) home closings by reportable segment for the three months ended March 31, 2026 and (ii) the Company’s owned or controlled lots by reportable segment as of March 31, 2026.

    Three Months Ended March 31, 2026


  As of March 31, 2026


Reportable Segment   Home Closings


  Owned

(1)



  Controlled


  Total


Central   296     18,696     326     19,022  
Southeast   219     12,962     1,700     14,662  
Northwest   66     5,799     1,314     7,113  
West   172     8,610     3,286     11,896  
Florida   128     5,126     1,209     6,335  
Total   881     51,193     7,835     59,028  

(1) Of the 51,193 owned lots as of March 31, 2026, 34,168 were raw/under development lots and 17,025 were finished lots. Finished lots included 2,266 completed homes, including information centers, and 1,355 homes in progress.



Backlog Data

As of the dates set forth below, the Company’s net orders, cancellation rate and ending backlog homes and value were as follows (dollars in thousands, unaudited):

    Three Months Ended March 31,

Backlog Data
  2026

(4)
  2025

(5)
Net orders (1)     1,221       1,437  
Cancellation rate (2)     45.6 %     16.3 %
Ending backlog – homes (3)     1,699       1,040  
Ending backlog – value (3)   $ 660,511     $ 406,166  

(1) Net orders are new (gross) orders for the purchase of homes during the period, less cancellations of existing purchase contracts during the period.

(2) Cancellation rate for a period is the total number of purchase contracts cancelled during the period divided by the total new (gross) orders for the purchase of homes during the period.

(3) Ending backlog consists of retail homes at the end of the period that are under a purchase contract that has been signed by homebuyers who have met preliminary financing criteria but have not yet closed and wholesale contracts with varying terms. Ending backlog is valued at the contract amount.

(4) As of March 31, 2026, the Company had 442 units related to bulk sales agreements associated with its wholesale business.

(5) As of March 31, 2025, the Company had 253 units related to bulk sales agreements associated with its wholesale business.



Non-GAAP Measures

In addition to the results reported in accordance with accounting principles generally accepted in the United States (“GAAP”), the Company has provided information in this press release relating to adjusted net income, adjusted basic earnings per share, adjusted diluted earnings per share, gross margin excluding inventory impairment, adjusted gross margin, and net debt to capital ratio.


Adjusted Net Income, Adjusted Basic Earnings per Share, and Adjusted Diluted Earnings per Share

Adjusted net income, adjusted basic earnings per share, and adjusted diluted earnings per share are non-GAAP financial measures used by management as supplemental measures in evaluating operating performance. The Company defines adjusted net income as net income less inventory impairment charges. The Company defines adjusted basic earnings per share as adjusted net income divided by weighted average basic shares outstanding. The Company defines adjusted diluted earnings per share as adjusted net income divided by weighted average diluted shares outstanding. Management believes that the presentation of adjusted net income, adjusted basic earnings per share, and adjusted diluted earnings per share provides useful information to investors because such measures isolate the impact that inventory impairment charges have on net income and earnings per share. However, because adjusted net income, adjusted basic earnings per share, and adjusted diluted earnings per share exclude the inventory impairment charge, which has real economic effects and could impact the Company’s results, the utility of adjusted net income, adjusted basic earnings per share, and adjusted diluted earnings per share as measures of the Company’s operating performance may be limited. In addition, other companies may not calculate adjusted net income, adjusted basic earnings per share, and adjusted diluted earnings per share in the same manner that the Company does. Accordingly, adjusted net income, adjusted basic earnings per share, and adjusted diluted earnings per share should be considered only as supplements to net income, basic earnings per share, and diluted earnings per share, respectively, as measures of the Company’s performance.

The following table reconciles adjusted net income to net income, which is the GAAP financial measure that management believes to be most directly comparable, and adjusted basic earnings per share and adjusted diluted earnings per share are calculated by dividing adjusted net income by basic or diluted weighted average shares outstanding, respectively (dollars in thousands, except earnings per share, unaudited):

    Three Months Ended March 31,


      2026       2025  
Net income   $ 2,160     $ 3,994  
Basic weighted average number of shares outstanding     23,149,912       23,396,470  
Basic earnings per share   $ 0.09     $ 0.17  
Diluted weighted average number of shares outstanding     23,219,224       23,466,746  
Diluted earnings per share   $ 0.09     $ 0.17  

    Three Months Ended March 31,


      2026       2025  
Net income   $ 2,160     $ 3,994  
Inventory impairment     4,681        
Tax impact due to above reconciling item     (1,225 )      
Adjusted net income   $ 5,616     $ 3,994  
           
Basic weighted average number of shares outstanding     23,149,912       23,396,470  
Adjusted basic earnings per share   $ 0.24     $ 0.17  
Diluted weighted average number of shares outstanding     23,219,224       23,466,746  
Adjusted diluted earnings per share   $ 0.24     $ 0.17  




Gross Margin Excluding Inventory Impairment and Adjusted Gross Margin

Gross margin excluding inventory impairment and adjusted gross margin are non-GAAP financial measures used by management as supplemental measures in evaluating operating performance. The Company defines gross margin excluding inventory impairment as gross margin less inventory impairment charges. The Company defines adjusted gross margin as gross margin excluding inventory impairment, less capitalized interest and adjustments resulting from the application of purchase accounting included in the cost of sales. Management believes gross margin excluding inventory impairment and adjusted gross margin are useful because they isolate the impact that capitalized interest, purchase accounting adjustments, and inventory impairment (as applicable) have on gross margin. However, because gross margin excluding inventory impairment and adjusted gross margin exclude capitalized interest, purchase accounting adjustments, and inventory impairment (as applicable), which have real economic effects and could impact the Company’s results, the utility of gross margin excluding inventory impairment and adjusted gross margin as measures of the Company’s operating performance may be limited. In addition, other companies may not calculate gross margin excluding inventory impairment and adjusted gross margin in the same manner that the Company does. Accordingly, gross margin excluding inventory impairment and adjusted gross margin should be considered only as supplements to gross margin as a measure of the Company’s performance.

The following table reconciles gross margin excluding inventory impairment and adjusted gross margin to gross margin, which is the GAAP financial measure that management believes to be most directly comparable (dollars in thousands, unaudited):

    Three Months Ended March 31,
      2026       2025  
Home sales revenues   $ 319,736     $ 351,420  
Cost of sales     259,807       277,707  
Gross margin   $ 59,929     $ 73,713  
Inventory impairment     4,681        
Gross margin excluding inventory impairment   $ 64,610     $ 73,713  
Capitalized interest charged to cost of sales     9,976       8,267  
Purchase accounting adjustments (1)     389       809  
Adjusted gross margin   $ 74,975     $ 82,789  
Gross margin % (2)     18.7 %     21.0 %
Gross margin % excluding inventory impairment (2)     20.2 %     21.0 %
Adjusted gross margin % (2)     23.4 %     23.6 %

(1) Adjustments result from the application of purchase accounting for acquisitions and represent the amount of the fair value step-up adjustments included in cost of sales for real estate inventory sold after the acquisition dates.

(2) Calculated as a percentage of home sales revenues.




Net Debt to Capital Ratio 

Net debt to capital ratio is a non-GAAP financial measure used by management as a supplemental measure in understanding the leverage employed in the Company’s operations and as an indicator of its ability to obtain financing. The Company defines net debt to capital ratio as net debt (which is total debt minus cash and cash equivalents) divided by net debt plus total equity. Management believes that the presentation of net debt to capital ratio provides useful information to investors regarding the Company’s financial leverage and its ability to meet long-term obligations. By excluding cash and cash equivalents from total debt, the ratio offers a clearer view of the Company’s capital structure and financial flexibility. Management uses this metric to monitor the Company’s capital efficiency and to evaluate the effectiveness of its capital management strategies over time. Other companies may define this measure differently and, as a result, the Company’s measure of net debt to capital ratio may not be directly comparable to the measures of other companies.

The following table reconciles net debt to capital ratio (a non-GAAP financial measure) to debt to capital ratio, which is the GAAP financial measure that management believes to be most directly comparable (dollars in thousands, unaudited):

    March 31, 2026   December 31, 2025
Total debt (Notes payable)   $ 1,709,457     $ 1,656,803  
Total equity     2,102,414       2,096,289  
Total capital   $ 3,811,871     $ 3,753,092  
Debt to capital ratio     44.8 %     44.1 %
         
Total debt (Notes payable)   $ 1,709,457     $ 1,656,803  
Less: Cash and cash equivalents     60,860       61,247  
Net debt   $ 1,648,597     $ 1,595,556  
Total equity     2,102,414       2,096,289  
Total net capital   $ 3,751,011     $ 3,691,845  
Net debt to capital ratio (1)     44.0 %     43.2 %

(1) Net debt to capital ratio is calculated as net debt (which is total debt minus cash and cash equivalents) divided by net debt plus total equity.

CONTACT: Joshua D. Fattor
Executive Vice President, Investor Relations and Capital Markets
(281) 210-2586
[email protected]



Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting

 Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-up results for the first four Cohort 1 completers, 24-month post-treatment follow-up results for the first Cohort 1 Patient, and interim clinical results for the first Cohort 2 Patient

 BB-301 is the only clinical-stage therapeutic agent in development for the treatment of dysphagia in patients diagnosed with OPMD

HAYWARD, Calif., April 28, 2026 (GLOBE NEWSWIRE) — Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced the acceptance of the interim clinical results from the ongoing BB-301 Phase 1b/2a first-in-human study for Oculopharyngeal Muscular Dystrophy (OPMD) with moderate dysphagia for oral presentation at the 2026 American Society of Gene and Cell Therapy Annual Meeting (ASGCT). Interim clinical results for patients enrolled into Cohort 1 and Cohort 2 will be discussed in an oral presentation at ASGCT, being held in Boston, MA from May 11 – 15, 2026.

Details regarding the BB-301 Oral Presentation are as follows: 

Session Name: Long-term safety and durable efficacy in cell and gene therapy
Presentation Date and Time: 05/15/2026, 09:15 AM – 09:30 AM
Location: MCEC Room 257AB (Level 2)
Abstract ID: 448
Presenter: Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer, Benitec Biopharma

About OPMD
There are currently no approved therapies for OPMD, a rare autosomal-dominant degenerative muscle disorder, that impacts nearly 15,000 patients in North America, Europe and Israel. OPMD is caused by a mutation in the poly(A)-binding protein nuclear 1 (PABPN1) gene; PABPN1 is a ubiquitous protein that controls the length of mRNA poly(A) tails, mRNA export from the nucleus and alternative poly(A) site usage. OPMD is a debilitating progressive disease that weakens the pharyngeal muscles, causing severe swallowing difficulties (dysphagia).1 Progressive dysphagia impacts 97% of OPMD patients and is a severe, life-threatening complication of OPMD which can lead to chronic choking, malnutrition, aspiration pneumonia and death.

About BB-301
BB-301 is a novel, modified AAV9 capsid expressing a unique, single bifunctional construct promoting co-expression of both codon-optimized Poly-A Binding Protein Nuclear-1 (PABPN1) and two small inhibitory RNAs (siRNAs) against mutant PABPN1 (the causative gene for OPMD). The two siRNAs are modeled into microRNA backbones to silence expression of faulty mutant PABPN1, while allowing expression of the codon-optimized PABPN1 to replace the mutant with a functional version of the protein. We believe the silence and replace mechanism of BB-301 is uniquely positioned for the treatment of OPMD by halting mutant PABPN1 expression while providing a functional replacement protein. BB-301 has received Orphan Drug Designation from the EMA and Orphan Drug and Fast Track Designations from the FDA.

About Benitec Biopharma Inc.
Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec’s website at www.benitec.com.

Forward Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release include forward-looking statements, including statements regarding Benitec’s plans to develop and commercialize its product candidates, the timing of the completion of pre-clinical and clinical trials, the timing of the availability of data from our clinical trials, the timing and sufficiency of patient enrollment and dosing in clinical trials, the timing of expected regulatory filings and other regulatory steps, and the clinical utility and potential attributes and benefits of ddRNAi and Benitec’s product candidates, and other forward-looking statements.

These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: the success of our plans to develop and potentially commercialize our product candidates; the timing of the completion of preclinical studies and clinical trials; the timing and sufficiency of patient enrollment and dosing in any future clinical trials; the timing of the availability of data from our clinical trials; the timing and outcome of regulatory filings and approvals; the development of novel AAV vectors; our potential future out-licenses and collaborations; the plans of licensees of our technology; the clinical utility and potential attributes and benefits of ddRNAi and our product candidates, including the potential duration of treatment effects and the potential for a “one shot” cure; our intellectual property position and the duration of our patent portfolio; expenses, ongoing losses, future revenue, capital needs and needs for additional financing, and our ability to access additional financing given market conditions and other factors; the length of time over which we expect our cash and cash equivalents to be sufficient to execute on our business plan; unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities and other regulatory developments; the Company’s ability to protect and enforce its patents and other intellectual property rights; the Company’s dependence on its relationships with its collaboration partners and other third parties; the efficacy or safety of the Company’s products and the products of the Company’s collaboration partners; the acceptance of the Company’s products and the products of the Company’s collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; the impact of, and our ability to remediate, the identified material weakness in our internal controls over financial reporting; the impact of local, regional, and national and international economic conditions and events; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission. The Company disclaims any intent or obligation to update these forward-looking statements.

References:

  1. https://www.mayoclinic.org/diseases-conditions/dysphagia/symptoms-causes/syc-20372028

Investor Relations Contact: 
Candice Masse
Astr Partners
(978) 879-7273
[email protected]

Media Contact:
Audra Friis
Sam Brown Healthcare Communications
(917) 519-9577
[email protected]



Chicago Atlantic BDC, Inc. Announces Date for First Quarter 2026 Results Release and Conference Call

NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) — Chicago Atlantic BDC, Inc. (the “Company”) (NASDAQ: LIEN), a specialty finance company that has elected to be regulated as a business development company, today announced details for the release of its financial results for the first quarter of 2026.

The Company plans to release its financial results for the first quarter ended March 31, 2026 before the market opens on Thursday, May 14, 2026, and host a conference call and live audio webcast, both open for the general public to hear, later that day at 9:00 a.m. Eastern Time. The number to call for the conference call is 833-630-1956 (international callers: 412-317-1837). The live audio webcast will be available on the Company’s website at investors.chicagoatlanticbdc.com.

A replay of the call will be available at investors.chicagoatlanticbdc.com by the end of day on May 14, 2026.

Call Details – Chicago Atlantic BDC, Inc. First Quarter 2026 Financial Results:

About Chicago Atlantic BDC, Inc.

The Company is a specialty finance company that has elected to be regulated as a business development company under the Investment Company Act of 1940, as amended, and has elected to be treated as a regulated investment company for U.S. federal income tax purposes. The Company’s investment objective is to maximize risk-adjusted returns on equity for its stockholders by investing primarily in direct loans to privately held middle-market companies, with a primary focus on cannabis companies. The Company is managed by Chicago Atlantic BDC Advisers, LLC, an investment manager focused on the cannabis industry and other niche or underfollowed sectors. For more information, please visit chicagoatlanticbdc.com.

Contact:

Tripp Sullivan
Lisa Kampf
SCR Partners, LLC
[email protected]



GXO Introduces Europe’s First Autoload System for Grupa Żywiec in Poland

Innovative automated solution speeds loading operations to two minutes while reducing material consumption, standardizing processes and enhancing safety

WARSAW, Poland, April 28, 2026 (GLOBE NEWSWIRE) —
GXO Logistics, Inc. (NYSE: GXO), the world’s largest pure‑play contract logistics provider, announced today that it has implemented the first Autoload system in Europe for Grupa Żywiec in Elbląg, one of the leading beer producers. The new technology significantly increases throughput, enhances workplace safety and elevates operational standards within the companies’ longstanding partnership.

“We are proud to introduce another joint innovation with Grupa Żywiec, our trusted partner for over seven years,” said Jean‑Luc Bessade, GXO’s Managing Director for Central Europe. “As a technology leader and early adopter of advanced automation, GXO continues to set new benchmarks for operational performance. With nearly 50% of our Central Europe revenue generated from automated operations, our continuous improvement mindset enables us to deliver measurable efficiency gains and support our customers’ long-term growth.”

Automation that transforms processes: faster, safer and more efficient

The Autoload system (Automated Truck Loader System), launched earlier this year, automates trailer loading and unloading, replacing traditional forklift operations. While standard processes require loading each pallet individually, Autoload completes the full trailer movement in a one‑shot cycle, reducing operation time to around two minutes. Its precise mechanical action eliminates human error risk, increases safety by reducing Material Handling Equipment activity in loading docks, ensures stable and repeatable process quality, and is scalable, with the ability to integrate with existing warehouse automation. The system also enables a higher number of transport movements using the same infrastructure, improving efficiency and reducing operational costs.

“In an increasingly complex food and beverage supply chain, GXO stands out as a trusted partner who understands our specific needs,” Michał Kalinowski, Contract Logistics Manager
Grupa Żywiec. “By leveraging advanced technology, GXO helps us boost productivity, safety and sustainability, allowing us to focus our resources on what matters most – growing our core business.”

To see the Autoload in action at GXO, click here.

Partnership rooted in sustainability and operational excellence

The Autoload installation is the latest innovation in a partnership that spans more than a decade. Over the course of the partnership, GXO and Grupa Żywiec have implemented several ESG initiatives which have delivered a significant reduction in energy consumption and a significant decrease in glass usage thanks to returns process improvements.

GXO remains a pioneer of advanced logistics solutions, with the rollout of Autoload supporting its Operational Excellence and continuous improvement approach. The launch builds on prior implementations which include AMR robots, ProGlove and Cognex scanners, automated packing solutions and integrated warehouse management systems to ensure seamless processes from production lines through to final delivery.

About GXO

GXO Logistics, Inc. (NYSE: GXO) is the world’s largest pure-play contract logistics provider and is positioned to capitalize on the rapid growth of ecommerce, automation and outsourcing. GXO has over 150,000 team members across more than 1,000 facilities, totaling more than 200 million square feet. The company serves the world’s leading blue-chip companies to solve complex logistics challenges with technologically advanced supply chain and ecommerce solutions, at scale and with speed. GXO corporate headquarters is in Greenwich, Connecticut. Visit GXO.com for more information and connect with GXO on LinkedInX, Facebook, Instagram and YouTube.

Media contacts

Barbara Tokarz
+48 538 626 625
[email protected]

Matthew Schmidt
+1 203-307-2809
[email protected]

Attachment



BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older

BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older

Approval based on KALOS and LOGOS Phase III trials demonstrating statistically significant and clinically meaningful benefits of AstraZeneca’s single-inhaler fixed-dose triple therapy compared with inhaled dual therapy

Approval is second indication for BREZTRI beyond COPD

WILMINGTON, Del.–(BUSINESS WIRE)–
AstraZeneca’s fixed-dose triple-combination therapy BREZTRI Aerosphere® (budesonide/glycopyrrolate/formoterol fumarate or BGF 320/36/9.6μg) has been approved in the US for the maintenance treatment of asthma in adult and pediatric patients 12 years of age and older. BREZTRI is a single-inhaler that combines the efficacy of corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines with a long-acting muscarinic antagonist (LAMA). BREZTRI (320/18/9.6μg) was approved in the US in 2020 to treat adults with chronic obstructive pulmonary disease (COPD) and was prescribed to more than 6.8 million patients globally in 2025.1,2

The approval by the US Food and Drug Administration (FDA) was based on efficacy and safety data from the Phase III KALOS and LOGOS trials investigating BREZTRI in a broad population consisting of patients with asthma, with or without a recent asthma exacerbation.3 In these trials, BREZTRI demonstrated a statistically significant and clinically meaningful improvement in lung function compared with dual-combination inhaled ICS/LABA.3 In a key secondary endpoint, BREZTRI also demonstrated a rapid onset of action with a significant improvement from baseline in lung function within five minutes after the first dose.3 BREZTRI is a maintenance therapy and is not used to relieve sudden breathing problems and will not replace a rescue inhaler.

Njira Lugogo, MD, Clinical Professor, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, said: “Despite the availability of dual maintenance therapy, many patients are still at risk for exacerbations and experience daily breathing difficulties, reduced lung function and the ongoing fear of worsening symptoms. The FDA approval ofBREZTRI as the only maintenance triple therapy for people with asthma 12 years of age and older marks a pivotal moment in helping those living with this debilitating disease breathe better, sooner.”

Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, AstraZeneca, said: “As the fastest growing fixed-dose triple-combination therapy in COPD,BREZTRI is already improving outcomes for people suffering with COPD, and we are proud to extend its benefits to asthma patients. The FDA’s approval of BREZTRI in asthma demonstrates how our innovative science continues to bring new solutions for patients with respiratory diseases.”

There are 27 million people living with asthma in the US,4 around half of whom continue to be uncontrolled on dual therapies, leading to inflammation and muscle tightening in the airway (bronchoconstriction) that cause wheezing, breathlessness, chest tightness, coughing exacerbations and even death.5,6 Nearly 10 million asthma attacks still occur each year in the US.4

Results from KALOS and LOGOS were published in The Lancet Respiratory Medicine in February 2026.3 There were no new safety or tolerability signals identified for BREZTRI in the trials.3

BREZTRI is a single-inhaler fixed-dose triple-combination therapy approved for the treatment of COPD in adults in 90 countries worldwide including the US, EU, China and Japan. Regulatory filings for BREZTRI in asthma are currently under review in other major regions including the EU, Japan and China.

IMPORTANT SAFETY INFORMATION

  • BREZTRI is contraindicated:

    • For the primary treatment of status asthmaticus or other acute episodes of asthma or COPD requiring intensive measures

    • In patients who have a hypersensitivity to budesonide, glycopyrrolate, formoterol fumarate or product excipients

  • Long-acting beta2-adrenergic agonist (LABA) monotherapy for asthma is associated with an increased risk of serious asthma-related events. These findings are considered a class effect of LABA monotherapy. When a LABA is used in a fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS use alone. Available data do not suggest an increased risk of death with use of LABA in patients with COPD

  • BREZTRI should not be initiated in patients with acutely deteriorating COPD or asthma, which may be a life-threatening condition

  • BREZTRI is NOT a rescue inhaler. Do NOT use to relieve acute symptoms; treat with an inhaled short-acting beta2-agonist

  • BREZTRI should not be used more often than recommended; at higher doses than recommended; or in combination with LABA-containing medicines, due to risk of overdose. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs

  • Oropharyngeal candidiasis has occurred in patients treated with orally inhaled drug products containing budesonide. Advise patients to rinse their mouths with water without swallowing after inhalation

  • Lower respiratory tract infections, including pneumonia, have been reported following ICS. Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of pneumonia and exacerbations frequently overlap

  • Due to possible immunosuppression, potential worsening of infections could occur. Use with caution. A more serious or fatal course of chickenpox or measles can occur in susceptible patients

  • Particular care is needed for patients transferred from systemic corticosteroids to ICS because deaths due to adrenal insufficiency have occurred in patients during and after transfer. Taper patients slowly from systemic corticosteroids if transferring to BREZTRI

  • Hypercorticism and adrenal suppression may occur with regular or very high dosage in susceptible individuals. If such changes occur, consider appropriate therapy

  • Caution should be exercised when considering the coadministration of BREZTRI with long-term ketoconazole and other known strong CYP3A4 Inhibitors. Adverse effects related to increased systemic exposure to budesonide may occur

  • If paradoxical bronchospasm occurs, discontinue BREZTRI immediately and institute alternative therapy

  • Anaphylaxis and other hypersensitivity reactions (eg, angioedema, urticaria or rash) have been reported. Discontinue and consider alternative therapy

  • Use caution in patients with cardiovascular disorders, especially coronary insufficiency, as formoterol fumarate can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, and also cardiac arrhythmias, such as supraventricular tachycardia and extrasystoles

  • Decreases in bone mineral density have been observed with long-term administration of ICS. Assess initially and periodically thereafter in patients at high risk for decreased bone mineral content

  • Monitor growth in pediatric patients

  • Glaucoma and cataracts may occur with long-term use of ICS. Worsening of narrow-angle glaucoma may occur, so use with caution. Consider referral to an ophthalmologist in patients who develop ocular symptoms or use BREZTRI long term. Instruct patients to contact a healthcare provider immediately if symptoms occur

  • Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to contact a healthcare provider immediately if symptoms occur

  • Use caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, and ketoacidosis or unusually responsive to sympathomimetic amines

  • Be alert to hypokalemia or hyperglycemia

  • Most common adverse reactions (incidence ≥ 2%) are:

    • COPD: upper respiratory tract infection, pneumonia, back pain, oral candidiasis, influenza, muscle spasms, urinary tract infection, cough, sinusitis, and diarrhea
    • Asthma: nasopharyngitis, pneumonia, and headache
  • BREZTRI should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors and tricyclic antidepressants, as these may potentiate the effect of formoterol fumarate on the cardiovascular system

  • BREZTRI should be administered with caution to patients being treated with:

    • Strong cytochrome P450 3A4 inhibitors (may cause systemic corticosteroid effects)

    • Adrenergic drugs (may potentiate effects of formoterol fumarate)

    • Xanthine derivatives, steroids, or non-potassium sparing diuretics (may potentiate hypokalemia and/or ECG changes)

    • Beta-blockers (may block bronchodilatory effects of beta-agonists and produce severe bronchospasm)

    • Anticholinergic-containing drugs (may interact additively). Avoid use with BREZTRI

  • Use BREZTRI with caution in patients with hepatic impairment, as budesonide and formoterol fumarate systemic exposure may increase. Patients with severe hepatic disease should be closely monitored

INDICATIONS

BREZTRI AEROSPHERE 160 mcg/9 mcg/4.8 mcg is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.

BREZTRI AEROSPHERE 160 mcg/18 mcg/4.8 mcg is indicated for the maintenance treatment of asthma in adult and pediatric patients 12 years of age and older.

LIMITATIONS OF USE

Not indicated for the relief of acute bronchospasm.

Please see full BREZTRI Prescribing Information, including Patient Information.

You mayreport side effects related to AstraZeneca products.

Notes

Asthma

Asthma is a prevalent, chronic respiratory disease affecting as many as 262 million people worldwide,8 including 27 million in the US.4 When uncontrolled, inflammation and muscle tightening in the airway (bronchoconstriction) may cause wheezing, breathlessness, chest tightness, coughing, and even death.5-7 Many patients remain uncontrolled despite the availability of standard of care medicines and continue to experience significant limitations on lung function and reduced quality of life.6,7

KALOS and LOGOS Phase III trials

KALOS and LOGOS were replicate confirmatory, randomised, double-blind, double-dummy, parallel group, multi-centre, 24-to-52-week variable length Phase III trials to assess the efficacy and safety of BREZTRI Aerosphere compared with Symbicort (budesonide/formoterol fumarate, a marketed therapeutic option), PT009 (budesonide/formoterol fumarate in an Aerosphere formulation) and the Symbicort and PT009 treatment groups combined.3,9,10 KALOS and LOGOS included approximately 4,300 randomised patients.

The primary endpoints for the two individual trials were a change from baseline in forced expiratory volume in 1 second (FEV1) area under the curve 0 to 3 hours (AUC0-3) at Week 24 and trough FEV1 over 12-24 weeks and over 24 weeks.3,9,10 The primary endpoints and treatment comparisons in the KALOS and LOGOS trials differed according to regulatory submission approaches. In the data package submitted to the US FDA, the primary lung function endpoint was change from baseline in FEV1 AUC0-3 at week 24, and the key secondary endpoint was change from baseline in morning pre-dose trough FEV1 at week 24, compared to PT009.3

BREZTRI/TRIXEO Aerosphere

Budesonide/glycopyrronium/formoterol fumarate or budesonide/glycopyrrolate/formoterol fumarate, is approved under the brand name BREZTRI Aerosphere in Japan, China and the US, and Trixeo Aerosphere in the EU, is a single-inhaler, fixed-dose triple-combination of formoterol fumarate, a LABA, glycopyrronium bromide, a long-acting muscarinic antagonist (LAMA), with budesonide, an ICS, and delivered via the Aerosphere pMDI. BREZTRI/TRIXEOAerosphere is approved to treat adults with COPD in 90 countries worldwide including the US, EU, China, Japan, and was prescribed to more than 6.8 million patients globally in 2025.2

AstraZeneca in Respiratory & Immunology

Respiratory & Immunology, part of AstraZeneca BioPharmaceuticals, is a key disease area and growth driver to the Company.

AstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in immune-mediated diseases. The Company is committed to addressing the vast unmet needs of these chronic, often debilitating, diseases with a pipeline and portfolio of inhaled medicines, biologics and new modalities aimed at previously unreachable biologic targets. Our ambition is to deliver life-changing medicines that help eliminate COPD as a leading cause of death, eliminate asthma attacks and achieve clinical remission in immune-mediated diseases.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

References

  1. AstraZeneca. Breztri Aerosphere approved in the US for the maintenance treatment of COPD. Press Release. 24 July 2020. Available at: https://www.astrazeneca.com/media-centre/press-releases/2020/breztri-aerosphere-approved-in-the-us-for-copd.html. [Last accessed: April 2026].

  2. AstraZeneca. Data On File. REF-325003.

  3. Papi A, et al. Budesonide/glycopyrronium/formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin phase 3, randomised, double-blind, double-dummy, parallel-group, multicentre trials. Lancet Respir. Med. 2026. Available at: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00457-6/abstract [Last accessed: April 2026].

  4. U.S. Centers for Disease Control and Prevention (CDC). Most Recent Asthma Data. [Online]. Available at: https://www.cdc.gov/asthma-data/about/most-recent-asthma-data.html [Last accessed: April 2026].

  5. Fernandes AG, et al. Risk factors for death in patients with severe asthma. J Bras Pneumol. 2014; 40 (4): 364-372.

  6. Davis J, et al. Burden of asthma among patients adherent to ICS/LABA: A real-world study. J Asthma. 2019 Mar;56(3):332-340.

  7. Buhl R, et al. One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting β2-agonist in UK primary care settings. Respir Med. 2020 Feb: 162:105859.

  8. Global Asthma Network. The Global Asthma Report 2022. [Online]. Available at: http://globalasthmareport.org/resources/Global_Asthma_Report_2022.pdf. [Last accessed: April 2026].

  9. Clinicaltrials.gov. Study to Assess PT010 in Adult and Adolescent Participants with Inadequately Controlled Asthma (KALOS) [Online]. Available at: https://clinicaltrials.gov/study/NCT04609878?limit=25&term=KALOS&rank=1. [Last accessed: April 2026].

  10. Clinicaltrials.gov. Study to Assess PT010 in Adult and Adolescent Participants with Inadequately Controlled Asthma (LOGOS) [Online]. Available at: https://clinicaltrials.gov/study/NCT04609904?limit=25&term=LOGOS&rank=4 [Last accessed: April 2026].

 

Media Inquiries

Fiona Cookson +1 212 814 3923

US Media Mailbox: [email protected]

KEYWORDS: Delaware United States North America

INDUSTRY KEYWORDS: FDA Health Clinical Trials General Health Pharmaceutical Biotechnology

MEDIA:

Sportradar Reports First Quarter 2026 Financial Results and Announces $250 Million Enhanced Open Market Share Repurchase Program


First


Quarter


2026


Highlights

  • Revenue increased 11% to €347 million
  • Loss for the period of €6 million, 1.8% as a percentage of revenue with increased operating results offset by unrealized foreign currency losses
  • Adjusted EBITDA1 increased 12% to €66 million and Adjusted EBITDA margin1 expanded to 19.0%
  • Net cash from operating activities of €109 million. Free cash flow1 increased 38% to €44 million
  • Achieved a Customer Net Retention Rate1 of 108% excluding contributions from IMG
  • Repurchased $90 million of shares under the share repurchase plan and announced a $250 million enhanced open market share repurchase program
  • Announced Sameer Deen to join Sportradar leadership team as Chief Operating Officer

ST. GALLEN, Switzerland, April 28, 2026 (GLOBE NEWSWIRE) — Sportradar Group AG (Nasdaq: SRAD) (“Sportradar” or the “Company”), a leading global sports technology company focused on creating immersive experiences for sports fans and bettors, today announced financial results for its first quarter ended March 31, 2026.

Carsten Koerl, Chief Executive Officer of Sportradar, said: “Sportradar’s first quarter growth reflects our premier position as the scaled leader in the expanding global sports data ecosystem. We continue to deepen our relationships across our expansive distribution network, providing additional content, products and services to our sportsbook, media and technology clients. Our recently acquired portfolio of IMG content has further bolstered our diverse offering and is resonating with customers worldwide while also expanding our margins as we increasingly leverage our existing infrastructure. Maximizing the opportunities our market leadership position and long-standing relationships remains our priority as we also begin to capitalize on new avenues of growth, including prediction markets and iGaming. Driving value for our partners and clients has always been our focus and continuing to do so should build additional shareholder value in the months and years ahead. Our confidence in our trajectory is demonstrated by the increased buyback activity this past quarter as well as the enhanced open market share repurchase program announced today.”

FIRST
QUARTER RESULTS


Revenue

    Three-Month Period Ended

March 31,
in € thousands (unaudited)   2026   2025   Change   %
Revenue by product                
Betting & Gaming Content   232,244   193,807   38,437     20 %
Managed Betting Services   55,361   56,214   (853 )   (2 )%
Betting Technology & Solutions   287,605   250,021   37,584     15 %
                 
Marketing & Media Services   42,453   46,610   (4,157 )   (9 )%
Sports Performance   10,676   11,411   (735 )   (6 )%
Integrity Services   5,784   3,189   2,595     81 %
Sports Content, Technology & Services   58,913   61,210   (2,297 )   (4 )%
Total Revenue   346,518   311,231   35,287     11 %
                 
Revenue by geography                
Rest of World   257,080   225,130   31,950     14 %
United States   89,438   86,101   3,337     4 %
Total Revenue   346,518   311,231        






FIRST QUARTER FINANCIAL RESULTS


Revenue

Total revenue for the first quarter was €347 million, up €35 million, or 11% year-over-year, driven by 15% growth in Betting Technology & Solutions, partially offset by a 4% decline in Sports Content, Technology & Services.

Betting Technology & Solutions revenues of €288 million were up 15% year-over-year primarily driven by a 20% increase in Betting & Gaming Content due to contributions related to the acquisition of IMG ARENA, uptake of the Company’s content and products, as well as U.S. market growth, partially offset by the significant impact of foreign currency movements. Managed Betting Services revenues declined 2%, as higher turnover in the Managed Trading Services business was offset by unfavorable sporting outcomes during the quarter.

Sports Content, Technology & Services revenues of €59 million declined 4% year-over-year primarily driven by a 9% decline in Marketing & Media Services, due primarily to a reduction in marketing campaigns from certain existing customers during the quarter, partially offset by increased revenue from Integrity Services.

The Company generated strong revenue growth globally with Rest of World up 14% and the United States up 4%. Foreign currency movements, particularly due to the U.S. dollar relative to the Euro, continue to negatively impact earnings. As a percentage of total Company revenues, United States revenue represented 26% of total Company revenue in the first quarter as compared to 28% in the prior year quarter.


Loss for the period

Loss for the period was €6 million, down €31 million, compared to a profit of €24 million in the same quarter a year ago, as the Company’s strong operating results were more than offset primarily by a foreign currency loss of €9 million versus a gain of €28 million in the same period a year ago, due principally to unrealized currency fluctuations mainly associated with U.S. dollar-denominated sports rights. The first quarter of 2026 also included higher depreciation and amortization and finance costs primarily related to the acquisition of IMG ARENA, partially offset by lower income taxes.


Adjusted EBITDA

First quarter Adjusted EBITDA was €66 million, up €7 million, or 12% compared to €59 million in the same quarter in 2025. The increase was largely driven by the 11% revenue growth, primarily offset by the inclusion of costs related to IMG ARENA, most notably sport rights.


Business Highlights

  • Announced key addition to Sportradar’s leadership team, naming Sameer Deen as Chief Operating Officer, commencing May 18, 2026.
  • Launched Playradar, a dedicated iGaming brand delivering hybrid sports-casino content to global operators across slots, table games, virtual sports, arcade, and crash games, operating exclusively in regulated markets.
  • Expanded the Company’s multi-year partnership with Hard Rock Bet, adding official PGA TOUR and UFC data and enhanced in-play betting capabilities including 3D shot tracking and micro markets.
  • Extended and expanded the Company’s integrity services agreement with FIFA for an additional five years through 2031, providing AI-driven bet-monitoring, intelligence and investigation support, and risk assessment services across FIFA’s 211 member associations and competitions worldwide.
  • Announced a multi-year partnership with the Liga Nacional de Basquete for worldwide rights for official data as well as audiovisual betting, completing Sportradar’s presence across Brazil’s three most popular sports.


Balance Sheet and Liquidity

The Company’s cash and cash equivalents were €322 million as of March 31, 2026, as compared with €365 million as of December 31, 2025. Net cash generated from operating activities for the three-months ended March 31, 2026 of €109 million was partially offset by net cash used in investing activities of €63 million, primarily from payments related to sport rights licenses, and by net cash used in financing activities of €93 million. Financing activities included €91 million in share repurchases. Free cash flow for the three-months ended March 31, 2026 was €44 million, an increase of €12 million from €32 million in the same period in 2025.

1 Non-IFRS measure. See the sections captioned “Non-IFRS Financial Measures and Operating Metric” and “IFRS to Non-IFRS reconciliations” for more details.

Including an undrawn credit facility, the Company had total liquidity of €542 million as of March 31, 2026, as compared to €585 million as of December 31, 2025, and no debt outstanding.


2026 Full Year Financial Outlook

Sportradar reiterated its fiscal 2026 outlook as follows:

  • Revenue growth on a Constant Currency1 basis of 23% to 25%. When factoring in current foreign currency rates, revenues are expected to grow to a range of €1,557 to €1,582 million
  • Adjusted EBITDA growth on a Constant Currency basis of 34% to 37%. When factoring in current foreign currency rates, Adjusted EBITDA is expected to grow to a range of €390 to €400 million
  • Adjusted EBITDA margin expansion of approximately 200 to 225 basis points
  • Free cash flow conversion1 rate is expected to exceed the 2025 level of 56%


Share Repurchase Plan

In March 2024, the Company’s Board of Directors approved a $200 million share repurchase plan. Subsequently, the Board of Directors approved a $100 million increase to the plan in October 2025 and another $700 million increase in February 2026, bringing the total authorized share repurchase plan to $1 billion. In addition, under this authorized plan, the Company today announced it has entered into an enhanced open market share repurchase program, to purchase up to $250 million of shares. As of April 24, 2026 the Company has repurchased 12.5 million shares or $228 million under the plan since inception, including $117 million in 2026.


Conference Call and Webcast Information

Sportradar will host a conference call to discuss the first quarter 2026 results today, April 28, 2026 at 8:00 a.m. Eastern Time. Those wishing to participate via webcast should access the earnings call through Sportradar’s Investor Relations website. An archived webcast with the accompanying slides will be available at the Company’s Investor Relations website for one year after the conclusion of the live event.


About Sportradar

Sportradar Group AG (Nasdaq: SRAD), founded in 2001, is a leading global sports technology company creating immersive experiences for sports fans and bettors. Positioned at the intersection of the sports, media and betting industries, the Company provides sports federations, news media, consumer platforms and sports betting operators with a best-in-class range of solutions to help grow their business. As the trusted partner of organizations like the ATP, NBA and WNBA, NHL, MLB, MLS, PGA TOUR, UEFA, FIFA, CONMEBOL, AFC, and the Bundesliga, Sportradar covers more than a million events annually across all major sports. With deep industry relationships and expertise, Sportradar is not just redefining the sports fan experience, it also safeguards sports through its Integrity Services division and advocacy for an integrity-driven environment for all involved.

For more information about Sportradar, please visit www.sportradar.com

CONTACT:

Investor Relations:

Jim Bombassei
[email protected]

Media:

Sandra Lee
[email protected]

1 Non-IFRS measure or Operating Metric. See the sections captioned “Non-IFRS Financial Measures and Operating Metric” and “IFRS to Non-IFRS reconciliations” for more details.


Non-IFRS Financial Measures and Operating Metric

We have provided in this press release financial information that has not been prepared in accordance with IFRS, including Adjusted EBITDA, Adjusted EBITDA margin, Constant Currency metrics, Adjusted purchased services, Adjusted personnel expenses, Adjusted other operating expenses, Free cash flow, and Free cash flow conversion, as well as our operating metric, Customer Net Retention Rate. We use these non-IFRS financial measures internally in analyzing our financial results and believe they are useful to investors, as a supplement to IFRS measures, in evaluating our ongoing operational performance. We believe that the use of these non-IFRS financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing our financial results with other companies in our industry, many of which present similar non-IFRS financial measures to investors.

Non-IFRS financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with IFRS. Investors are encouraged to review the reconciliation of these non-IFRS financial measures to their most directly comparable IFRS financial measures provided in the financial statement tables included below in this press release.

  • “Adjusted EBITDA” represents earnings for the period adjusted for finance income and finance costs, income tax expense or benefit, depreciation and amortization (excluding amortization of capitalized sport rights licenses), foreign currency gains or losses, and other items that are non-recurring or not related to the Company’s revenue-generating operations, including share-based compensation, restructuring costs, non-routine litigation costs, and certain transaction-related costs.

    License fees relating to sport rights are a key component of how we generate revenue and one of our main operating expenses. Only licenses that meet the recognition criteria of IAS 38 are capitalized. The primary distinction for whether a license is capitalized or not capitalized is the contracted length of the applicable license. Therefore, the type of license we enter into can have a significant impact on our results of operations depending on whether we are able to capitalize the relevant license. As such, our presentation of Adjusted EBITDA reflects the full costs of our sport rights licenses. Management believes that, by including amortization of sport rights in its calculation of Adjusted EBITDA, the result is a financial metric that is both more meaningful and comparable for management and our investors while also being more indicative of our ongoing operating performance.

    We present Adjusted EBITDA because management believes that some items excluded are non-recurring in nature and this information is relevant in evaluating the results relative to other entities that operate in the same industry. Management believes Adjusted EBITDA is useful to investors for evaluating Sportradar’s operating performance against competitors, which commonly disclose similar performance measures. However, Sportradar’s calculation of Adjusted EBITDA may not be comparable to other similarly titled performance measures of other companies. Adjusted EBITDA is not intended to be a substitute for any IFRS financial measure.

    Items excluded from Adjusted EBITDA include significant components in understanding and assessing financial performance. Adjusted EBITDA has limitations as an analytical tool and should not be considered in isolation, or as an alternative to, or a substitute for, profit for the period, revenue or other financial statement data presented in our consolidated financial statements as indicators of financial performance. We compensate for these limitations by relying primarily on our IFRS results and using Adjusted EBITDA only as a supplemental measure.

  • “Adjusted EBITDA margin” is the ratio of Adjusted EBITDA to revenue.

    The Company is unable to provide a reconciliation of Adjusted EBITDA to profit (loss) for the period, or Adjusted EBITDA margin to Profit (loss) for the period as a percentage of revenue (in each case, the most directly comparable IFRS financial measure) on a forward-looking basis without unreasonable effort because items that impact these IFRS financial measures are not within the Company’s control and/or cannot be reasonably predicted. These items may include, but are not limited to, foreign exchange gains and losses. Such information may have a significant, and potentially unpredictable, impact on the Company’s future financial results.

  • Constant Currency” information compares results between periods as if exchange rates had remained constant. As the impact of exchange rate fluctuations can be highly variable, we believe these metrics, unaffected by exchange rate variability, provide meaningful insights to investors into our operational performance and underlying business trends.

    The Company is unable to provide a reconciliation of constant currency measures to their comparable IFRS measures on a forward-looking basis without unreasonable effort because future exchange-rate movements that impact these measures are not within the Company’s control and/or cannot be reasonably predicted. Such information may have a significant, and potentially unpredictable, impact on the Company’s future financial results.

We present Adjusted purchased services, Adjusted personnel expenses, and Adjusted other operating expenses (together, “Non-IFRS expenses”) because management utilizes these financial measures to manage its business on a day-to-day basis and believes that they are the most relevant measures of expenses. Management believes these adjusted expense measures provide expanded insight to assess revenue and cost performance, in addition to the standard IFRS-based financial measures. Management believes these adjusted expense measures are useful to investors for evaluating Sportradar’s operating performance against competitors. However, Sportradar’s calculation of adjusted expense measures may not be comparable to other similarly titled performance measures of other companies. These adjusted expense measures are not intended to be a substitute for any IFRS financial measure.

  • Adjusted purchased services” represents purchased services less capitalized external development costs and certain transaction-related costs.
  • Adjusted personnel expenses” represents personnel expenses less share-based compensation awarded to employees, restructuring costs, and capitalized personnel compensation.
  • Adjusted other operating expenses” represents other operating expenses plus impairment loss on trade receivables, less non-routine litigation, share-based compensation awarded to third parties, and certain transaction-related costs.

We consider Free cash flow and Free cash flow conversion to be liquidity measures that provide useful information to management and investors about the amount of cash generated by the business after the purchase of property and equipment, the purchase of intangible assets and payment of lease liabilities, which can then be used, among other things, to invest in our business and make strategic acquisitions, as well as our ability to convert our earnings to cash. A limitation of the utility of Free cash flow and Free cash flow conversion as measures of liquidity is that they do not represent the total increase or decrease in our cash balance for the year.

  • Free cash flow” represents net cash from operating activities adjusted for payments for lease liabilities, acquisition of property and equipment, and acquisition of intangible assets.
  • Free cash flow conversion” represents Free cash flow as a percentage of Adjusted EBITDA.

    The Company is unable to provide a reconciliation of Free cash flow to net cash from operating activities or Free cash flow conversion to net cash from operating activities as a percentage of profit (loss) for the period (in each case, the most directly comparable IFRS financial measure) on a forward-looking basis without unreasonable effort because items that impact these IFRS financial measures are not within the Company’s control and/or cannot be reasonably predicted. These items may include, but are not limited to, changes in working capital, the timing of customer payments, the timing and amount of tax payments, and other items that are non-recurring or unusual. Such information may have a significant, and potentially unpredictable, impact on the Company’s future financial results.

In addition, we define the following operating metric as follows:

  • “Customer Net Retention Rate” is calculated for a given period by starting with the reported Trailing Twelve Month revenue from our top 200 customers as of twelve months prior to such period end, or prior period revenue. We then calculate the reported trailing twelve-month revenue from the same customer cohort as of the current period end, or current period revenue. Current period revenue includes any upsells and is net of contraction and attrition over the trailing twelve months but excludes revenue from new customers in the current period. We then divide the total current period revenue by the total prior period revenue to arrive at our Net Retention Rate.


Safe Harbor for Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking” statements and information within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 that relate to our current expectations and views of future events, including, without limitation, statements regarding future financial or operating performance, planned activities and objectives, anticipated growth resulting therefrom, market opportunities, strategies and other expectations, the IMG ARENA acquisition and its accretive nature and our guidance and outlook, including expected performance for the full year 2026, as well as statements regarding our share repurchase plan including the New Repurchase Program. In some cases, these forward-looking statements can be identified by words or phrases such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “seek,” “believe,” “estimate,” “predict,” “potential,” “projects”, “continue,” “contemplate,” “confident,” “possible” or similar words. These forward-looking statements are subject to risks, uncertainties and assumptions, some of which are beyond our control. In addition, these forward-looking statements reflect our current views with respect to future events and are not a guarantee of future performance. Actual outcomes may differ materially from the information contained in the forward-looking statements as a result of a number of factors, including, without limitation, the following: economic downturns and political and market conditions beyond our control, including uncertainty and instability resulting from catastrophic events such as acts of war or terrorism and foreign exchange rate fluctuations; dependence on our strategic relationships with our sports league partners; effect of social responsibility concerns and public opinion on responsible gaming, gambling by minors, match-fixing or other illegal gambling schemes on our reputation; potential adverse changes in public and consumer tastes and preferences and industry trends; potential changes in competitive landscape, including new market entrants or disintermediation; potential inability to anticipate and adopt new technology and products; potential errors, failures or bugs in our products; inability to protect our systems and data from continually evolving cybersecurity risks, security breaches or other technological risks; potential interruptions and failures in our systems or infrastructure; our ability to comply with governmental laws, rules, regulations, and other legal obligations, related to data privacy, protection and security; ability to comply with the variety of unsettled and developing U.S. and foreign laws on sports betting; risks associated with artificial intelligence and machine-learning technologies; failure to recruit, retain and develop qualified personnel; changes in the legal and regulatory status of real money gambling and betting legislation on us and our customers; our inability to maintain or obtain regulatory compliance in the jurisdictions in which we conduct our business; our ability to obtain, maintain, protect, enforce and defend our intellectual property rights; our ability to obtain and maintain sufficient data rights from major sports leagues, including exclusive rights; our ability to successfully remediate any material weaknesses identified in our internal control over financial reporting; seasonality and volatility; difficulties in our ability to evaluate, complete and integrate acquisitions successfully (including the integration of the IMG ARENA business); inability to secure additional financing in a timely manner, or at all, to meet our long-term future capital needs; publication of research reports, including by short sellers, or speculation in the press or the investment community, about us; and other risk factors set forth in the section titled “Risk Factors” in our Annual Report on Form 20-F for the fiscal year ended December 31, 2025, and other documents filed with or furnished to the SEC, accessible on the SEC’s website at www.sec.gov and on our website at https://investors.sportradar.com. These statements reflect management’s current expectations regarding future events and operating performance and speak only as of the date of this press release. One should not put undue reliance on any forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

SPORTRADAR GROUP AG

CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

(Unaudited)

    Three-Month Period Ended

March 31,
in €’000, except share and per share data   2026
  2025
Revenue   346,518     311,231  
Personnel expenses   (106,499 )   (102,356 )
Sport rights expenses (including amortization of capitalized sport rights licenses)   (122,293 )   (104,030 )
Purchased services   (48,275 )   (48,989 )
Other operating expenses   (29,367 )   (28,114 )
Impairment loss on trade receivables, contract assets and other financial assets   (2,047 )   (1,737 )
Internally-developed software cost capitalized   6,934     11,656  
Depreciation and amortization (excluding amortization of capitalized sport rights licenses)   (19,530 )   (16,318 )
Foreign currency (loss) gain, net   (9,278 )   27,524  
Finance income   3,293     2,333  
Finance costs   (24,322 )   (21,853 )
Net (loss) income before tax   (4,866 )   29,347  
Income tax expense   (1,421 )   (5,009 )
(Loss) profit for the period   (6,287 )   24,338  
         
Other comprehensive income        
Items that will not be reclassified subsequently to profit or (loss)        
Remeasurement of defined benefit (liability)   3     (2 )
Related deferred tax benefit       28  
    3     26  
Items that may be reclassified subsequently to profit or (loss)        
Foreign currency translation adjustment attributable to the owners of the company   2,177     (4,937 )
Foreign currency translation adjustment attributable to non-controlling interests       (226 )
    2,177     (5,163 )
Other comprehensive income (loss) for the period, net of tax   2,180     (5,137 )
Total comprehensive (loss) income for the period   (4,107 )   19,201  
         
(Loss) profit attributable to:        
Owners of the Company   (6,286 )   24,208  
Non-controlling interests   (1 )   130  
    (6,287 )   24,338  
Total comprehensive (loss) income attributable to:        
Owners of the Company   (4,106 )   19,297  
Non-controlling interests   (1 )   (96 )
    (4,107 )   19,201  
         
(Loss) profit per Class A share attributable to owners of the Company        
Basic   (0.02 )   0.08  
Diluted   (0.02 )   0.07  
(Loss) profit per Class B share attributable to owners of the Company        
Basic   (0.00 )   0.01  
Diluted   (0.00 )   0.01  
         
Weighted-average number of shares        
Weighted-average number of Class A shares (basic)   219,229     210,610  
Weighted-average number of Class A shares (diluted)   235,830     230,413  
Weighted-average number of Class B shares (basic and diluted)   783,671     903,671  





SPORTRADAR GROUP AG

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

(Unaudited)

in €’000   March 31,

2026
  December 31,

2025
Assets        
Current assets        
Cash and cash equivalents   321,787     365,295  
Trade receivables   99,808     93,552  
Contract assets   112,813     123,456  
Other assets and prepayments   86,406     72,287  
Income tax receivables   16,695     15,884  
Total current assets   637,509     670,474  
Non-current assets        
Property and equipment   77,891     79,343  
Intangible assets and goodwill   1,945,394     2,033,653  
Other financial assets and other non-current assets   62,051     60,517  
Deferred tax assets   29,274     28,748  
Total non-current assets   2,114,610     2,202,261  
Total assets   2,752,119     2,872,735  
Liabilities and equity        
Current liabilities        
Loans and borrowings   10,924     11,010  
Trade payables   446,899     426,857  
Other liabilities   94,032     94,677  
Contract liabilities   42,769     35,195  
Income tax liabilities   8,493     6,891  
Total current liabilities   603,117     574,630  
Non-current liabilities        
Loans and borrowings   50,693     51,842  
Trade payables   1,146,640     1,209,876  
Contract liabilities   36,722     38,024  
Other non-current liabilities   3,945     3,880  
Deferred tax liabilities   12,830     16,146  
Total non-current liabilities   1,250,830     1,319,768  
Total liabilities   1,853,947     1,894,398  
Equity        
Ordinary shares   27,582     27,582  
Treasury shares   (123,124 )   (79,388 )
Additional paid-in capital   668,732     682,475  
Retained earnings   317,186     342,051  
Other reserves   7,795     5,615  
Equity attributable to owners of the Company   898,171     978,335  
Non-controlling interest   1     2  
Total equity   898,172     978,337  
Total liabilities and equity   2,752,119     2,872,735  





SPORTRADAR GROUP AG

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

    Three-Month Period Ended

March 31,
in €’000   2026
  2025
OPERATING ACTIVITIES:        
(Loss) profit for the period   (6,287 )   24,338  
Adjustments to reconcile profit for the period to net cash provided by operating activities:        
Income tax expense   1,421     5,009  
Interest income   (2,015 )   (2,333 )
Interest expense   24,322     21,853  
Foreign currency loss (gain), net   9,278     (27,524 )
Depreciation and amortization (excluding amortization of capitalized sport rights licenses)   19,530     16,318  
Amortization of capitalized sport rights licenses   88,125     71,699  
Equity-settled share-based payments   15,346     12,847  
Other   510     (149 )
Cash flow from operating activities before working capital changes, interest and income taxes   150,230     122,058  
Increase in trade receivables, contract assets, other assets and prepayments   (7,306 )   (17,882 )
(Increase) decrease in trade and other payables, contract and other liabilities   (5,175 )   21,570  
Changes in working capital   (12,481 )   3,688  
Interest paid   (24,170 )   (21,646 )
Interest received   738     2,333  
Income taxes paid, net   (5,085 )   (4,187 )
Net cash from operating activities   109,232     102,246  
INVESTING ACTIVITIES:        
Acquisition of intangible assets   (60,904 )   (67,325 )
Acquisition of property and equipment   (2,286 )   (972 )
Acquisition of subsidiaries, net of cash acquired       2,654  
Proceeds from sale of intangible assets   1     21  
Change in loans receivable and deposits   (18 )   (188 )
Net cash used in investing activities   (63,207 )   (65,810 )
FINANCING ACTIVITIES:        
Payment of lease liabilities   (2,000 )   (1,999 )
Purchase of treasury shares   (91,419 )   (16,611 )
Net cash used in financing activities   (93,419 )   (18,610 )
Net (decrease) increase in cash   (47,394 )   17,826  
Cash and cash equivalents at beginning of period   365,295     348,357  
Effects of movements in exchange rates   3,886     (8,358 )
Cash and cash equivalents at end of period   321,787     357,825  






Additional disclosures related to sport rights expenses

The following table shows the composition of sport rights expenses (unaudited):

    Three-Month Period Ended

March 31,
in €’000   2026   2025
Non-capitalized sport rights expenses   34,168   32,331
Amortization of capitalized sport rights   88,125   71,699
Total sport rights expenses   122,293   104,030


IFRS to Non-IFRS Reconciliations

The following table reconciles Adjusted EBITDA to the most directly comparable IFRS financial performance measure, which is (Loss) profit for the period (unaudited), and Adjusted EBITDA margin to the most directly comparable IFRS financial performance measure, which is (Loss) profit for the period (unaudited) as a percentage of revenue:

    Three-Month Period Ended

March 31,
in €’000   2026
  2025
Revenue   346,518     311,231  
         
(Loss) profit for the period   (6,287 )   24,338  
Finance income   (3,293 )   (2,333 )
Finance costs   24,322     21,853  
Depreciation and amortization (excluding amortization of capitalized sport rights licenses)   19,530     16,318  
Foreign currency loss (gain), net   9,278     (27,524 )
Share-based compensation   16,801     14,541  
Restructuring costs   1,109     1,342  
Non-routine litigation costs   2,012     2,279  
Transaction-related costs   1,113     3,132  
Income tax expense   1,421     5,009  
Adjusted EBITDA   66,006     58,955  
             
(Loss) profit for the period as a percentage of revenue
  (1.8 )%   7.8 %
Adjusted EBITDA margin
  19.0 %   18.9 %

The most directly comparable IFRS measure of Free cash flow is Net cash from operating activities, and the most directly comparable IFRS measure of Free cash flow conversion is Net cash from operating activities conversion, which is measured as Net cash from operating activities as a percentage of (Loss) profit for the period. Calculations for these measures are disclosed below (unaudited):

    Three-Month Period Ended

March 31,
in €’000   2026
  2025
Net cash from operating activities   109,232     102,246  
Acquisition of intangible assets   (60,904 )   (67,325 )
Acquisition of property plant and equipment   (2,286 )   (972 )
Payment of lease liabilities   (2,000 )   (1,999 )
Free cash flow   44,042     31,950  
             
Net cash from operating activities conversion   (1,737 )%   420 %
Free cash flow conversion
  67 %   54 %

The following tables show reconciliations of IFRS expenses included in (Loss) profit for the period to expenses included in Adjusted EBITDA (unaudited):

    Three-Month Period Ended

March 31,
in €’000   2026
  2025
Purchased services   48,275     48,989  
Less: capitalized external services   (2,501 )   (5,283 )
Less: transaction-related costs   (22 )    
Adjusted purchased services   45,752     43,706  
         
Personnel expenses   106,499     102,356  
Less: share-based compensation   (17,100 )   (15,239 )
Less: restructuring costs   (1,109 )   (1,342 )
Less: capitalized personnel compensation   (3,858 )   (5,455 )
Adjusted personnel expenses   84,432     80,320  
         
Other operating expenses   29,367     28,114  
Less: non-routine litigation   (2,012 )   (2,279 )
Less: share-based compensation   (276 )   (220 )
Less: transaction-related costs   (1,091 )   (3,132 )
Add: impairment loss on trade receivables   2,047     1,737  
Adjusted other operating expenses   28,035     24,220  



U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

  • NDA submission based on the Phase 2b REZILIENT1 clinical trial, which demonstrated clinically meaningful and durable responses in patients with relapsed EGFR exon 20 insertion–mutated NSCLC
  • Prescription Drug User Fee Act (PDUFA) target action date is February 27, 2027

PRINCETON, N.J. & TOKYO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for zipalertinib for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations whose disease has progressed on or after platinum-based chemotherapy, with or without amivantamab. The Prescription Drug User Fee Act (PDUFA)target action date is February 27, 2027.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427550531/en/

The NDA is supported by data from the Phase 2b part of the REZILIENT1 clinical trial of zipalertinib monotherapy in patients with NSCLC harboring EGFR ex20ins mutations who have received prior therapy. The study met its primary endpoint of objective response rate. Study results from REZILIENT1 were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in the Journal of Clinical Oncology.

“Zipalertinib was discovered at Taiho Pharmaceutical Co., Ltd., and has been developed with a focus on addressing the unmet needs of patients with EGFR exon 20 insertion-mutated non-small cell lung cancer,” said Harold Keer, MD, PhD, Chief Medical Officer, Taiho Oncology. “The FDA’s acceptance of the NDA for zipalertinib is an important milestone for this program, and we look forward to working with FDA during the review process.”

“Zipalertinib is a compound created using Taiho Pharmaceutical’s proprietary drug discovery and development technologies, Cysteinomix, with the aim of delivering a new treatment option to address high unmet medical needs,” said Takeshi Sagara, PhD, Executive Director, Board Member, Medical Affairs, Translational Development, Clinical Development, Discovery and Preclinical Research at Taiho Pharmaceutical. “The FDA’s acceptance of the NDA represents an important milestone, reflecting the scientific and clinical data accumulated to date. We will continue to work closely with Taiho Oncology, Cullinan Therapeutics and the FDA throughout the review process, with the shared goal of ultimately delivering a new treatment option to patients with non-small cell lung cancer EGFR exon 20 insertion mutations.”

“FDA acceptance of the zipalertinib NDA is an important step toward making zipalertinib available for people living with non-small cell lung cancer with EGFR exon 20 insertion mutations, who continue to face limited treatment options,” said Jeffrey Jones, MD, MBA, Chief Medical Officer, Cullinan Therapeutics. “We are deeply grateful to the patients and families who have participated in the REZILIENT program, and to the investigators, study teams, and advocates whose collaboration made achievement of this milestone possible. We believe zipalertinib has the potential to help address a significant unmet need, and we look forward to working with our partners at Taiho with the goal of bringing zipalertinib to patients waiting for new treatment options.”

Summary of Primary Study Results:

  • Zipalertinib demonstrated clinically meaningful efficacy in the primary efficacy population (n=176), including 51 patients who had received prior amivantamab.

  • The confirmed objective response rate (ORR) was 35%. Median duration of response (mDOR) was 8.8 months.

  • In patients treated after prior platinum-based chemotherapy only (n=125), ORR was 40% with a mDOR of 8.8 months.

  • In exploratory subgroup analyses:

    • Patients who had received prior amivantamab without other ex20ins-targeted therapy (n=30) showed a confirmed ORR of 30% and mDOR of 14.7 months.

      Patients with brain metastases (n=68) showed a confirmed ORR of 31% and a mDOR of 8.3 months.

  • The safety profile of zipalertinib was manageable and consistent with previously reported data.¹ The most common treatment-emergent adverse events were paronychia, rash, anemia, dermatitis acneiform, diarrhea, dry skin, nausea and stomatitis. Most treatment-emergent adverse events were grade 1 or 2 per NCI-Common Terminology Criteria for Adverse Events (CTCAE v5.0).

Zipalertinib is an oral EGFR tyrosine kinase inhibitor. Zipalertinib received Breakthrough Therapy Designation in 2021 for the treatment of patients with locally advanced or metastatic NSCLC harboring EGFR ex20ins mutations who have previously received platinum‑based systemic chemotherapy.

About REZILIENT1

REZILIENT1 (Researching Zipalertinib in EGFR Non-Small Cell Lung Cancer Tumors) is a Phase 1/2 clinical trial (NCT04036682) to evaluate efficacy and safety of zipalertinib in adult patients with locally advanced or metastatic NSCLC harboring EGFR ex20ins mutations who have received prior therapy. Patients were treated with oral zipalertinib 100 mg twice daily. The primary endpoints were objective response rate (ORR) and duration of response (DOR) as assessed by blinded independent central review (ICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Adverse events were characterized and graded according to the NCI-Common Terminology Criteria for Adverse Events (CTCAE v5.0).

About Zipalertinib

Zipalertinib (development code: CLN-081/TAS6417) is an orally available small molecule designed to target activating mutations in EGFR. The molecule was selected because of its ability to inhibit EGFR variants with ex20ins mutations, while sparing wild-type EGFR. Zipalertinib is designed as a next generation, irreversible EGFR inhibitor for the treatment of a genetically defined subset of patients with non-small cell lung cancer. Zipalertinib has received Breakthrough Therapy Designation from the FDA for the treatment of patients with locally advanced or metastatic NSCLC harboring epidermal growth factor EGFR ex20ins mutations who have previously received platinum-based systemic chemotherapy. Zipalertinib is investigational and has not been approved by any health authority.

Zipalertinib is being developed by Taiho Oncology, Inc., and its parent company, Taiho Pharmaceutical Co., Ltd. worldwide, and in collaboration with Cullinan Therapeutics, Inc. in the U.S.

About EGFR Exon 20 Insertion Mutations

NSCLC is a common form of lung cancer and up to 4% of all cases globally have EGFR ex20ins, which makes them the third most common EGFR mutation subtype.2 In the United States, approximately 16% of patients with NSCLC harbor EGFR mutations,2 with insertions at exon 20 accounting for up to 12% of these mutations.3

About Taiho Oncology, Inc.

The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development and commercialization of orally administered anti-cancer agents for various tumor types. Taiho Oncology has a robust pipeline of small-molecule clinical candidates targeting solid-tumor and hematological malignancies, with additional candidates in pre-clinical development. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company’s European and Canadian operations, which are located in Baar, Switzerland and Oakville, Ontario, Canada.

For more information, visit https://www.taihooncology.com/, and follow us on LinkedIn and X.

Taiho Oncology and the Taiho Oncology logo are registered trademarks of Taiho Pharmaceutical Co., Ltd.

About Taiho Pharmaceutical Co., Ltd. (Japan)

Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd. (https://www.otsuka.com/en/), is an R&D-driven specialty pharma focusing on the fields of oncology and immune-related diseases. Its corporate philosophy takes the form of a pledge: “We strive to improve human health and contribute to a society enriched by smiles.” In the field of oncology, in particular, Taiho Pharmaceutical is known as a leading company in Japan for developing innovative medicines for the treatment of cancer, a reputation that is rapidly expanding through their extensive global R&D efforts. In areas other than oncology, as well, the company creates and markets quality products that effectively treat medical conditions and can help improve people’s quality of life. Always putting customers first, Taiho Pharmaceutical also aims to offer consumer healthcare products that support people’s efforts to lead fulfilling and rewarding lives. For more information about Taiho Pharmaceutical, please visit https://www.taiho.co.jp/en.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, high-impact therapies for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow Cullinan on LinkedIn and X.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding the company’s beliefs and expectations regarding the potential for zipalertinib to obtain FDA approval for the treatment of patients with locally advanced or metastatic NSCLC harboring EGFR ex20ins mutations whose disease has progressed on or after platinum-based chemotherapy, with or without amivantamab, the anticipated timing of such FDA approval, the safety and efficacy profile of zipalertinib and its potential to address unmet medical need, and other statements that are not historical facts. The words “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “potential,” “project,” “pursue,” “will,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: uncertainty regarding the timing and results of regulatory submissions; the risk that any NDAs, INDs or other regulatory submissions we may file with the United States Food and Drug Administration or other global regulatory agencies are not accepted or cleared on our expected timelines, or at all; the success of our clinical trials and preclinical studies; the risks related to our ability to protect and maintain our intellectual property position; the risks related to manufacturing, supply, and distribution of our product candidates; the risk that any one or more of our product candidates, including those that are co-developed, will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; the effect of changes in global economic conditions, including uncertainties related to international trade policies, tariffs and supply chain dynamics on our business and operations; and the success of any collaboration, partnership, license or similar agreements. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, including under the caption “Risk Factors” in our most recent Annual Report on Form 10-K and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except to the extent required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Moreover, except as required by law, neither the company nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made.

References

  1. Piotrowska Z, Tan DS, Smit EF, et al. Safety, tolerability, and antitumor activity of zipalertinib among patients with non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions. Journal of Clinical Oncology. Available at: https://ascopubs.org/doi/full/10.1200/JCO.23.00152.

  2. Burnett H, Emich H, Carroll C, et al. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. PLOS ONE. 2021;16(3):e0247620. Available at: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0247620.

  3. Riess JW, Gandara DR, Frampton GM, et al. Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. Journal of Thoracic Oncology. 2018 Jul 5;13(10):1560–1568. Available at: https://www.jto.org/article/S1556-0864(18)30770-6/pdf.

Taiho Oncology

Leigh Labrie

+1 609.664.9878

[email protected]

Taiho Pharmaceutical Co., Ltd.

Junko Onishi

+81-80-1009-7683

[email protected]

Cullinan Therapeutics

Investors

Nick Smith

+1 401.241.3516

[email protected]

Media

Rose Weldon

+1 215.801.7644

[email protected]

KEYWORDS: Massachusetts New Jersey United States Japan North America Asia Pacific

INDUSTRY KEYWORDS: Oncology Health FDA Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Logo
Logo
Logo
Logo
Logo
Logo

Polestar Decouples Growth From Negative Climate Impact: Emissions Per Sold Car Cut by 31% in Five Years

Polestar Decouples Growth From Negative Climate Impact: Emissions Per Sold Car Cut by 31% in Five Years

  • “If you are not reducing emissions while growing, you are choosing not to,” says Michael Lohscheller, CEO Polestar

  • Europe’s only pure EV company continues to deliver measurable progress instead of pledges, despite a volatile and challenged industry.

  • Polestar 0 project: Large scale pilot for ultra-low-emission steel among progress

GOTHENBURG, Sweden–(BUSINESS WIRE)–
Polestar (Nasdaq: PSNY) today publishes its 2025 Sustainability Report, showing how the Company has since 2020 reduced its GHG emissions per sold car by 31%. During the same period, Polestar has scaled its business and grown annual retail sales to over 60,000 cars, expanded across 28 markets, brought three new models to the road and established manufacturing in factories across three countries.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428383744/en/

As climate commitments slip across the car industry, policy signals waver and combustion engine investment continues, Polestar moves in the opposite direction: forward. Europe’s only pure EV company continues to deliver measurable progress instead of pledges, despite a volatile and challenged industry.

The reduction in emissions per sold car since 2020 reflects the Company’s focus on increasing renewable energy use related to battery production and manufacturing, and use of low-carbon materials. Over the past year, increased volumes of Polestar 4, the company’s lowest carbon footprint car to date, has also been a significant factor, alongside the expansion of renewable energy across key European markets, which drives down use-phase emissions. Europe remains Polestar’s largest market, representing over 75% of sales. Polestar continues to stay below its emissions reduction curve, heading towards its goal of becoming a climate-neutral company by 2040.

Michael Lohscheller, Polestar CEO, says: “If you are not reducing emissions while growing, you are choosing not to. Electrification delivers clear value for customers: lower running costs, lower emissions and greater peace of mind, as volatile oil prices and fuel scarcity mean pump anxiety is increasingly replacing range anxiety. As clean electricity scales, electric vehicles are becoming not just the sustainable choice, but the smarter, more reliable one.”

At a societal level, electrification offers a clear path to reducing lifecycle GHG emissions from passenger transport, as renewable energy and EV adoption scale together. As electricity becomes cleaner and more stable than petroleum-based fuels, the role of electric vehicles as a climate solution is becoming even more evident.

Recent results from the Polestar 0 project

Work at the Mission 0 House in Gothenburg brings together industry and academia to eliminate emissions from high-impact materials, products, and processes. This research is driving new materials, technologies, and partnerships toward the Polestar 0 project goal of a net-zero car without offsets by 2035. The initial 2030 timeline has been revised, reflecting the scale and complexity of the challenge, but also the opportunity. On the contrary of giving up, Polestar consolidates the task through the dedicated research in the Mission 0 House.

Fredrika Klarén, Head of Sustainability at Polestar, says: “The Polestar 0 project pushes us into new territory. While much of the industry invests in hybrids and combustion engines, we focus on solutions that eliminate emissions entirely. The innovation emerging from this project shows the power of collaboration and material science, and importantly, how well positioned we are to move the industry forward.”

Key developments from Mission 0 House include:

  • Large-scale pilot for ultra-low-emission steel

  • Research on materials for batteries

  • Development of bio-based textile alternatives

  • Technologies converting CO₂ into new materials

Mission 0 House was formally established in 2025, securing close to SEK 100 million in funding over five years towards the research consortium. The current collaboration includes five Swedish higher education institutions and six companies.

Notes to editors

Mission 0 House

Since 2024, Polestar’s climate research is centered in Mission 0 House in Gothenburg, together with academia and different industries to eliminate emissions from materials, products, and processes.

Following a pilot phase, Mission 0 House was formally established in 2025, securing close to SEK 100 million in funding. The aim is to develop scalable solutions and patents that support climate-neutral materials and products and help manufacturers reduce emissions.

Research is organised across metals, chemicals, and processes, with interdisciplinary teams working closely together. During 2025, new partners joined and projects expanded, strengthening Mission 0 House as a platform for applied research and collaboration. The current collaboration includes five Swedish higher education institutions, University of Borås, University West, Jönköping University, Karlstad University, and Mid Sweden University, alongside companies Borgstena, Polestar, Sekab, SSAB, TMG Automotive, and Together Tech, with additional financial support from the Knowledge Foundation, Vinnova and Västra Götalandsregionen.

Read more on: www.Mission0House.org

About Polestar

Polestar (Nasdaq: PSNY) is the Swedish electric performance car brand with a focus on uncompromised design and innovation, and the ambition to accelerate the change towards a sustainable future. Headquartered in Gothenburg, Sweden, its cars are available in 28 markets globally across North America, Europe and Asia Pacific.

Polestar has four models in its line-up: Polestar 2, Polestar 3, Polestar 4, and Polestar 5. Planned models include the Polestar 7 compact SUV (to be introduced in 2028) and the Polestar 6 roadster. With its vehicles currently manufactured on two continents, North America and Asia, Polestar plans to diversify its manufacturing footprint further, with production of Polestar 7 planned in Europe.

Polestar has an unwavering commitment to sustainability and has set an ambitious roadmap to reach its climate targets: halve greenhouse gas emissions by 2030 per-vehicle-sold and become climate-neutral across its value chain by 2040. Polestar’s comprehensive sustainability strategy covers the four areas of Climate, Transparency, Circularity, and Inclusion.

Forward-Looking Statements

This press release contains statements that are not historical facts, but rather forward-looking statements within the meaning of Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that address activities, events or developments that Polestar or its management believes or anticipates may occur in the future. All forward-looking statements are based upon, as applicable, our current expectations, various assumptions and data available from third parties. Our expectations and assumptions are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that such forward-looking statements will materialize or prove to be correct as forward-looking statements are inherently subject to known and unknown risks, uncertainties and other factors which may cause actual future results, performance or achievements to differ materially from the future results, performance or achievements expressed in or implied by such forward-looking statements. Numerous risks, uncertainties and other factors may cause actual results to differ materially from those set out in the forward-looking statements, including those risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in Polestar’s Form 20-F, and other documents filed, or to be filed, with the U.S. Securities and Exchange Commission by Polestar. For any forward-looking statements contained in this or any other document, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we assume no obligation to update publicly or revise any such statements in light of new information or future events, except as required by law.

Ellen Broomé

[email protected]

KEYWORDS: Europe Sweden United States North America

INDUSTRY KEYWORDS: Environment Alternative Vehicles/Fuels EV/Electric Vehicles Climate Change Automotive General Automotive Automotive Manufacturing Sustainability Manufacturing Green Technology

MEDIA:

Logo
Logo